WO2024145168A1 - Compositions et méthodes pour traiter le cancer - Google Patents
Compositions et méthodes pour traiter le cancer Download PDFInfo
- Publication number
- WO2024145168A1 WO2024145168A1 PCT/US2023/085419 US2023085419W WO2024145168A1 WO 2024145168 A1 WO2024145168 A1 WO 2024145168A1 US 2023085419 W US2023085419 W US 2023085419W WO 2024145168 A1 WO2024145168 A1 WO 2024145168A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amount
- fold increase
- increase over
- therapeutic agent
- active agent
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 77
- 238000000034 method Methods 0.000 title claims abstract description 72
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 42
- 201000011510 cancer Diseases 0.000 title claims abstract description 19
- 210000004027 cell Anatomy 0.000 claims abstract description 759
- 102000004127 Cytokines Human genes 0.000 claims abstract description 219
- 108090000695 Cytokines Proteins 0.000 claims abstract description 219
- 108020004999 messenger RNA Proteins 0.000 claims abstract description 43
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims abstract description 36
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims abstract description 36
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims abstract description 32
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims abstract description 32
- 210000003463 organelle Anatomy 0.000 claims abstract description 7
- 108010065805 Interleukin-12 Proteins 0.000 claims description 116
- 102000013462 Interleukin-12 Human genes 0.000 claims description 116
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 88
- 229940117681 interleukin-12 Drugs 0.000 claims description 86
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 73
- 229920001184 polypeptide Polymers 0.000 claims description 70
- 230000008685 targeting Effects 0.000 claims description 70
- 239000012634 fragment Substances 0.000 claims description 53
- 239000000427 antigen Substances 0.000 claims description 51
- 108091007433 antigens Proteins 0.000 claims description 51
- 102000036639 antigens Human genes 0.000 claims description 51
- 201000010099 disease Diseases 0.000 claims description 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 31
- 239000003112 inhibitor Substances 0.000 claims description 30
- 102000015696 Interleukins Human genes 0.000 claims description 23
- 108010063738 Interleukins Proteins 0.000 claims description 23
- 239000008194 pharmaceutical composition Substances 0.000 claims description 18
- 230000028993 immune response Effects 0.000 claims description 16
- 210000002865 immune cell Anatomy 0.000 claims description 15
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims description 14
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims description 14
- 239000012270 PD-1 inhibitor Substances 0.000 claims description 13
- 239000012668 PD-1-inhibitor Substances 0.000 claims description 13
- 229940121655 pd-1 inhibitor Drugs 0.000 claims description 13
- 230000008073 immune recognition Effects 0.000 claims description 12
- 239000012528 membrane Substances 0.000 claims description 12
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 claims description 10
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 claims description 10
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 10
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 9
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims description 9
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims description 9
- 230000001939 inductive effect Effects 0.000 claims description 9
- 230000001988 toxicity Effects 0.000 claims description 9
- 231100000419 toxicity Toxicity 0.000 claims description 9
- 238000001943 fluorescence-activated cell sorting Methods 0.000 claims description 8
- 235000000346 sugar Nutrition 0.000 claims description 8
- 239000012275 CTLA-4 inhibitor Substances 0.000 claims description 7
- 229940125563 LAG3 inhibitor Drugs 0.000 claims description 7
- 239000012271 PD-L1 inhibitor Substances 0.000 claims description 7
- 229940125555 TIGIT inhibitor Drugs 0.000 claims description 7
- 230000003247 decreasing effect Effects 0.000 claims description 7
- 210000000265 leukocyte Anatomy 0.000 claims description 7
- 229940121656 pd-l1 inhibitor Drugs 0.000 claims description 7
- 102100034925 P-selectin glycoprotein ligand 1 Human genes 0.000 claims description 6
- 101710137390 P-selectin glycoprotein ligand 1 Proteins 0.000 claims description 6
- 238000002560 therapeutic procedure Methods 0.000 claims description 6
- 238000012384 transportation and delivery Methods 0.000 claims description 6
- 102100028989 C-X-C chemokine receptor type 2 Human genes 0.000 claims description 5
- 108010018951 Interleukin-8B Receptors Proteins 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 210000000952 spleen Anatomy 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 4
- 210000002615 epidermis Anatomy 0.000 claims description 4
- 230000002440 hepatic effect Effects 0.000 claims description 4
- 238000001727 in vivo Methods 0.000 claims description 4
- 230000001926 lymphatic effect Effects 0.000 claims description 4
- 230000033289 adaptive immune response Effects 0.000 claims description 2
- 230000015788 innate immune response Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 description 1337
- 229940124597 therapeutic agent Drugs 0.000 description 1333
- 239000013543 active substance Substances 0.000 description 1281
- 102000003812 Interleukin-15 Human genes 0.000 description 85
- 108090000172 Interleukin-15 Proteins 0.000 description 85
- 239000013598 vector Substances 0.000 description 32
- 230000004048 modification Effects 0.000 description 30
- 238000012986 modification Methods 0.000 description 30
- 230000013595 glycosylation Effects 0.000 description 25
- 238000006206 glycosylation reaction Methods 0.000 description 25
- -1 or portion thereof Substances 0.000 description 24
- 108090000623 proteins and genes Proteins 0.000 description 24
- 238000009472 formulation Methods 0.000 description 23
- 235000018102 proteins Nutrition 0.000 description 23
- 102000004169 proteins and genes Human genes 0.000 description 23
- 230000028327 secretion Effects 0.000 description 22
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 21
- 230000001965 increasing effect Effects 0.000 description 19
- 230000002401 inhibitory effect Effects 0.000 description 18
- 210000000130 stem cell Anatomy 0.000 description 18
- 230000007159 enucleation Effects 0.000 description 17
- 230000004807 localization Effects 0.000 description 17
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 17
- 230000014509 gene expression Effects 0.000 description 15
- 108020004414 DNA Proteins 0.000 description 14
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 14
- 239000000090 biomarker Substances 0.000 description 14
- 125000003275 alpha amino acid group Chemical group 0.000 description 13
- 210000002889 endothelial cell Anatomy 0.000 description 13
- 239000003446 ligand Substances 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 13
- 230000035899 viability Effects 0.000 description 13
- 102000053602 DNA Human genes 0.000 description 12
- 210000004940 nucleus Anatomy 0.000 description 12
- 102000005962 receptors Human genes 0.000 description 12
- 108020003175 receptors Proteins 0.000 description 12
- 230000004913 activation Effects 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 11
- 210000004072 lung Anatomy 0.000 description 10
- 210000004379 membrane Anatomy 0.000 description 10
- 150000003384 small molecules Chemical class 0.000 description 10
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 description 9
- 108010074708 B7-H1 Antigen Proteins 0.000 description 9
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 9
- 210000001744 T-lymphocyte Anatomy 0.000 description 9
- 210000000170 cell membrane Anatomy 0.000 description 9
- 239000004055 small Interfering RNA Substances 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- 102000019034 Chemokines Human genes 0.000 description 8
- 108010012236 Chemokines Proteins 0.000 description 8
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 8
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 8
- 241000700605 Viruses Species 0.000 description 8
- 230000003511 endothelial effect Effects 0.000 description 8
- 229940126546 immune checkpoint molecule Drugs 0.000 description 8
- 230000002452 interceptive effect Effects 0.000 description 8
- 210000005061 intracellular organelle Anatomy 0.000 description 8
- 108010076504 Protein Sorting Signals Proteins 0.000 description 7
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 7
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 7
- 210000004504 adult stem cell Anatomy 0.000 description 7
- 239000006185 dispersion Substances 0.000 description 7
- 210000002540 macrophage Anatomy 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 108091026890 Coding region Proteins 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 101000655352 Homo sapiens Telomerase reverse transcriptase Proteins 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 210000002919 epithelial cell Anatomy 0.000 description 6
- 210000003743 erythrocyte Anatomy 0.000 description 6
- 210000003527 eukaryotic cell Anatomy 0.000 description 6
- 238000010362 genome editing Methods 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 210000000440 neutrophil Anatomy 0.000 description 6
- 239000002243 precursor Substances 0.000 description 6
- 238000001890 transfection Methods 0.000 description 6
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 6
- 102100038078 CD276 antigen Human genes 0.000 description 5
- 102000009410 Chemokine receptor Human genes 0.000 description 5
- 108050000299 Chemokine receptor Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 102100028970 HLA class I histocompatibility antigen, alpha chain E Human genes 0.000 description 5
- 102100028967 HLA class I histocompatibility antigen, alpha chain G Human genes 0.000 description 5
- 108010024164 HLA-G Antigens Proteins 0.000 description 5
- 101000986085 Homo sapiens HLA class I histocompatibility antigen, alpha chain E Proteins 0.000 description 5
- 102000004890 Interleukin-8 Human genes 0.000 description 5
- 108090001007 Interleukin-8 Proteins 0.000 description 5
- 102000018697 Membrane Proteins Human genes 0.000 description 5
- 108010052285 Membrane Proteins Proteins 0.000 description 5
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 5
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 5
- 108010067787 Proteoglycans Proteins 0.000 description 5
- 102000016611 Proteoglycans Human genes 0.000 description 5
- 108091027967 Small hairpin RNA Proteins 0.000 description 5
- 108020004459 Small interfering RNA Proteins 0.000 description 5
- 239000000443 aerosol Substances 0.000 description 5
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 5
- 210000001772 blood platelet Anatomy 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 210000004209 hair Anatomy 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 210000003097 mucus Anatomy 0.000 description 5
- 210000001778 pluripotent stem cell Anatomy 0.000 description 5
- 230000011664 signaling Effects 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 102100036678 Interleukin-27 subunit alpha Human genes 0.000 description 4
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 4
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 4
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 4
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 description 4
- 101710090983 T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 description 4
- 102100024568 Tumor necrosis factor ligand superfamily member 11 Human genes 0.000 description 4
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 4
- 210000003651 basophil Anatomy 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000005907 cancer growth Effects 0.000 description 4
- 239000003636 conditioned culture medium Substances 0.000 description 4
- 238000013270 controlled release Methods 0.000 description 4
- 238000005138 cryopreservation Methods 0.000 description 4
- 210000004443 dendritic cell Anatomy 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 210000003979 eosinophil Anatomy 0.000 description 4
- 210000004907 gland Anatomy 0.000 description 4
- 210000003630 histaminocyte Anatomy 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 229950006780 n-acetylglucosamine Drugs 0.000 description 4
- 239000002105 nanoparticle Substances 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 230000000717 retained effect Effects 0.000 description 4
- 210000004918 root sheath Anatomy 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 210000002536 stromal cell Anatomy 0.000 description 4
- 210000000106 sweat gland Anatomy 0.000 description 4
- 210000001685 thyroid gland Anatomy 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 3
- 102100022464 5'-nucleotidase Human genes 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 102100034608 Angiopoietin-2 Human genes 0.000 description 3
- 108010048036 Angiopoietin-2 Proteins 0.000 description 3
- 102000016605 B-Cell Activating Factor Human genes 0.000 description 3
- 108010028006 B-Cell Activating Factor Proteins 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 3
- 108010056102 CD100 antigen Proteins 0.000 description 3
- 108010062802 CD66 antigens Proteins 0.000 description 3
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 3
- 102100024533 Carcinoembryonic antigen-related cell adhesion molecule 1 Human genes 0.000 description 3
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 3
- 102100025473 Carcinoembryonic antigen-related cell adhesion molecule 6 Human genes 0.000 description 3
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 3
- 102100037354 Ectodysplasin-A Human genes 0.000 description 3
- 102100037813 Focal adhesion kinase 1 Human genes 0.000 description 3
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 3
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 3
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 description 3
- 101000914326 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 6 Proteins 0.000 description 3
- 101000832225 Homo sapiens Stabilin-1 Proteins 0.000 description 3
- 101001102797 Homo sapiens Transmembrane protein PVRIG Proteins 0.000 description 3
- 101000863873 Homo sapiens Tyrosine-protein phosphatase non-receptor type substrate 1 Proteins 0.000 description 3
- 102000003814 Interleukin-10 Human genes 0.000 description 3
- 108090000174 Interleukin-10 Proteins 0.000 description 3
- 108090000176 Interleukin-13 Proteins 0.000 description 3
- 102000003816 Interleukin-13 Human genes 0.000 description 3
- 102000004556 Interleukin-15 Receptors Human genes 0.000 description 3
- 108010017535 Interleukin-15 Receptors Proteins 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 102000000588 Interleukin-2 Human genes 0.000 description 3
- 108010002386 Interleukin-3 Proteins 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 101150069255 KLRC1 gene Proteins 0.000 description 3
- 241000713666 Lentivirus Species 0.000 description 3
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 3
- 101100404845 Macaca mulatta NKG2A gene Proteins 0.000 description 3
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 3
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 description 3
- 101710150918 Macrophage colony-stimulating factor 1 receptor Proteins 0.000 description 3
- 206010027458 Metastases to lung Diseases 0.000 description 3
- 108700011259 MicroRNAs Proteins 0.000 description 3
- 101150065403 NECTIN2 gene Proteins 0.000 description 3
- 102100022682 NKG2-A/NKG2-B type II integral membrane protein Human genes 0.000 description 3
- 102100035488 Nectin-2 Human genes 0.000 description 3
- 108700020796 Oncogene Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 102100027744 Semaphorin-4D Human genes 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 102100024471 Stabilin-1 Human genes 0.000 description 3
- 230000006044 T cell activation Effects 0.000 description 3
- 102100039630 Transmembrane protein PVRIG Human genes 0.000 description 3
- 102100035283 Tumor necrosis factor ligand superfamily member 18 Human genes 0.000 description 3
- 102100029948 Tyrosine-protein phosphatase non-receptor type substrate 1 Human genes 0.000 description 3
- 241000711975 Vesicular stomatitis virus Species 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 210000000270 basal cell Anatomy 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000002975 chemoattractant Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000003013 erythroid precursor cell Anatomy 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 210000002175 goblet cell Anatomy 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 210000004919 hair shaft Anatomy 0.000 description 3
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 3
- 108010044426 integrins Proteins 0.000 description 3
- 102000006495 integrins Human genes 0.000 description 3
- 229940047122 interleukins Drugs 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000001365 lymphatic vessel Anatomy 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 206010061289 metastatic neoplasm Diseases 0.000 description 3
- 239000002679 microRNA Substances 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 210000000822 natural killer cell Anatomy 0.000 description 3
- 210000002394 ovarian follicle Anatomy 0.000 description 3
- 230000001817 pituitary effect Effects 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 210000002345 respiratory system Anatomy 0.000 description 3
- 210000003079 salivary gland Anatomy 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 210000002105 tongue Anatomy 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 230000002485 urinary effect Effects 0.000 description 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 239000000592 Artificial Cell Substances 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108020000946 Bacterial DNA Proteins 0.000 description 2
- 241000195940 Bryophyta Species 0.000 description 2
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 2
- 102000007499 CD27 Ligand Human genes 0.000 description 2
- 108010046080 CD27 Ligand Proteins 0.000 description 2
- 102100027207 CD27 antigen Human genes 0.000 description 2
- 102000004634 CD30 Ligand Human genes 0.000 description 2
- 108010017987 CD30 Ligand Proteins 0.000 description 2
- 102100032937 CD40 ligand Human genes 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 2
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 2
- 102000000844 Cell Surface Receptors Human genes 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 2
- 108010008951 Chemokine CXCL12 Proteins 0.000 description 2
- 102000006573 Chemokine CXCL12 Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 241000218631 Coniferophyta Species 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 2
- 102000001301 EGF receptor Human genes 0.000 description 2
- 108060006698 EGF receptor Proteins 0.000 description 2
- 108091029865 Exogenous DNA Proteins 0.000 description 2
- 229920001917 Ficoll Polymers 0.000 description 2
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
- 101100232738 Gallus gallus IFNL3 gene Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 102100035716 Glycophorin-A Human genes 0.000 description 2
- 108091005250 Glycophorins Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 101000897480 Homo sapiens C-C motif chemokine 2 Proteins 0.000 description 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 2
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 2
- 101000880080 Homo sapiens Ectodysplasin-A Proteins 0.000 description 2
- 101000920078 Homo sapiens Elongation factor 1-alpha 1 Proteins 0.000 description 2
- 101000878536 Homo sapiens Focal adhesion kinase 1 Proteins 0.000 description 2
- 101000998146 Homo sapiens Interleukin-17A Proteins 0.000 description 2
- 101000960946 Homo sapiens Interleukin-19 Proteins 0.000 description 2
- 101001010591 Homo sapiens Interleukin-20 Proteins 0.000 description 2
- 101001010626 Homo sapiens Interleukin-22 Proteins 0.000 description 2
- 101000853009 Homo sapiens Interleukin-24 Proteins 0.000 description 2
- 101000853002 Homo sapiens Interleukin-25 Proteins 0.000 description 2
- 101000853000 Homo sapiens Interleukin-26 Proteins 0.000 description 2
- 101000852998 Homo sapiens Interleukin-27 subunit alpha Proteins 0.000 description 2
- 101001043821 Homo sapiens Interleukin-31 Proteins 0.000 description 2
- 101000998139 Homo sapiens Interleukin-32 Proteins 0.000 description 2
- 101001055222 Homo sapiens Interleukin-8 Proteins 0.000 description 2
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 2
- 101001128431 Homo sapiens Myeloid-derived growth factor Proteins 0.000 description 2
- 101001117312 Homo sapiens Programmed cell death 1 ligand 2 Proteins 0.000 description 2
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 2
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 description 2
- 101000851434 Homo sapiens Tumor necrosis factor ligand superfamily member 13B Proteins 0.000 description 2
- 101000597779 Homo sapiens Tumor necrosis factor ligand superfamily member 18 Proteins 0.000 description 2
- 101000638161 Homo sapiens Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 2
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 description 2
- 102000026633 IL6 Human genes 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 108090000177 Interleukin-11 Proteins 0.000 description 2
- 102000003815 Interleukin-11 Human genes 0.000 description 2
- 102100036701 Interleukin-12 subunit beta Human genes 0.000 description 2
- 101710187487 Interleukin-12 subunit beta Proteins 0.000 description 2
- 102100020789 Interleukin-15 receptor subunit alpha Human genes 0.000 description 2
- 101710107699 Interleukin-15 receptor subunit alpha Proteins 0.000 description 2
- 101800003050 Interleukin-16 Proteins 0.000 description 2
- 102000049772 Interleukin-16 Human genes 0.000 description 2
- 102100033461 Interleukin-17A Human genes 0.000 description 2
- 102000003810 Interleukin-18 Human genes 0.000 description 2
- 108090000171 Interleukin-18 Proteins 0.000 description 2
- 102100039879 Interleukin-19 Human genes 0.000 description 2
- 102100030692 Interleukin-20 Human genes 0.000 description 2
- 102100030704 Interleukin-21 Human genes 0.000 description 2
- 102100030703 Interleukin-22 Human genes 0.000 description 2
- 108010065637 Interleukin-23 Proteins 0.000 description 2
- 102000013264 Interleukin-23 Human genes 0.000 description 2
- 102100036671 Interleukin-24 Human genes 0.000 description 2
- 102100036680 Interleukin-25 Human genes 0.000 description 2
- 102100036679 Interleukin-26 Human genes 0.000 description 2
- 108010066979 Interleukin-27 Proteins 0.000 description 2
- 102000000646 Interleukin-3 Human genes 0.000 description 2
- 102100021596 Interleukin-31 Human genes 0.000 description 2
- 102100033501 Interleukin-32 Human genes 0.000 description 2
- 108010067003 Interleukin-33 Proteins 0.000 description 2
- 102000017761 Interleukin-33 Human genes 0.000 description 2
- 108091007973 Interleukin-36 Proteins 0.000 description 2
- 102100026236 Interleukin-8 Human genes 0.000 description 2
- 102000000585 Interleukin-9 Human genes 0.000 description 2
- 108010002335 Interleukin-9 Proteins 0.000 description 2
- 102000017578 LAG3 Human genes 0.000 description 2
- 241000270322 Lepidosauria Species 0.000 description 2
- 102100032352 Leukemia inhibitory factor Human genes 0.000 description 2
- 229940125568 MGD013 Drugs 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 101100262697 Mus musculus Axl gene Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 102000004473 OX40 Ligand Human genes 0.000 description 2
- 108010042215 OX40 Ligand Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 108010025832 RANK Ligand Proteins 0.000 description 2
- 238000003559 RNA-seq method Methods 0.000 description 2
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 2
- 101100215487 Sus scrofa ADRA2A gene Proteins 0.000 description 2
- 108091046869 Telomeric non-coding RNA Proteins 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 108010065323 Tumor Necrosis Factor Ligand Superfamily Member 13 Proteins 0.000 description 2
- 102100024598 Tumor necrosis factor ligand superfamily member 10 Human genes 0.000 description 2
- 102100024585 Tumor necrosis factor ligand superfamily member 13 Human genes 0.000 description 2
- 102100036922 Tumor necrosis factor ligand superfamily member 13B Human genes 0.000 description 2
- 102100024586 Tumor necrosis factor ligand superfamily member 14 Human genes 0.000 description 2
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 description 2
- 108700005077 Viral Genes Proteins 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 210000002383 alveolar type I cell Anatomy 0.000 description 2
- 210000002588 alveolar type II cell Anatomy 0.000 description 2
- 210000002255 anal canal Anatomy 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229950002916 avelumab Drugs 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 210000002228 beta-basophil Anatomy 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000001045 blue dye Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000000233 bronchiolar non-ciliated Anatomy 0.000 description 2
- 229960001838 canakinumab Drugs 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000017455 cell-cell adhesion Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 210000001612 chondrocyte Anatomy 0.000 description 2
- 210000003737 chromaffin cell Anatomy 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- 230000001054 cortical effect Effects 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- OSVXSBDYLRYLIG-UHFFFAOYSA-N dioxidochlorine(.) Chemical compound O=Cl=O OSVXSBDYLRYLIG-UHFFFAOYSA-N 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 241001493065 dsRNA viruses Species 0.000 description 2
- 229950009791 durvalumab Drugs 0.000 description 2
- 229940056913 eftilagimod alfa Drugs 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 229940115415 enapotamab vedotin Drugs 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 210000003238 esophagus Anatomy 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000013265 extended release Methods 0.000 description 2
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 210000001156 gastric mucosa Anatomy 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229930004094 glycosylphosphatidylinositol Natural products 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 2
- 102000044409 human EEF1A1 Human genes 0.000 description 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 2
- 230000005931 immune cell recruitment Effects 0.000 description 2
- 229940126533 immune checkpoint blocker Drugs 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 108010074108 interleukin-21 Proteins 0.000 description 2
- 210000004966 intestinal stem cell Anatomy 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 229960005386 ipilimumab Drugs 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 210000001756 lactotroph Anatomy 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000001730 macula densa epithelial cell Anatomy 0.000 description 2
- 210000005075 mammary gland Anatomy 0.000 description 2
- 210000004216 mammary stem cell Anatomy 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 210000003593 megakaryocyte Anatomy 0.000 description 2
- 210000002752 melanocyte Anatomy 0.000 description 2
- 210000003584 mesangial cell Anatomy 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 210000003550 mucous cell Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000000663 muscle cell Anatomy 0.000 description 2
- 229940105132 myristate Drugs 0.000 description 2
- 210000000581 natural killer T-cell Anatomy 0.000 description 2
- 210000000933 neural crest Anatomy 0.000 description 2
- 210000001178 neural stem cell Anatomy 0.000 description 2
- 210000004498 neuroglial cell Anatomy 0.000 description 2
- 210000001719 neurosecretory cell Anatomy 0.000 description 2
- 229960003301 nivolumab Drugs 0.000 description 2
- 239000012457 nonaqueous media Substances 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 244000309459 oncolytic virus Species 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 210000002997 osteoclast Anatomy 0.000 description 2
- 210000001711 oxyntic cell Anatomy 0.000 description 2
- 210000003889 oxyphil cell of parathyroid gland Anatomy 0.000 description 2
- 210000003134 paneth cell Anatomy 0.000 description 2
- 210000002655 parathyroid chief cell Anatomy 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 229960002621 pembrolizumab Drugs 0.000 description 2
- 210000001539 phagocyte Anatomy 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 230000000541 pulsatile effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000001995 reticulocyte Anatomy 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 210000001625 seminal vesicle Anatomy 0.000 description 2
- 210000000717 sertoli cell Anatomy 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000007921 solubility assay Methods 0.000 description 2
- 210000001764 somatotrope Anatomy 0.000 description 2
- 210000004988 splenocyte Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000002381 testicular Effects 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 102000035160 transmembrane proteins Human genes 0.000 description 2
- 108091005703 transmembrane proteins Proteins 0.000 description 2
- 238000003211 trypan blue cell staining Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 210000003708 urethra Anatomy 0.000 description 2
- 210000001215 vagina Anatomy 0.000 description 2
- 210000005166 vasculature Anatomy 0.000 description 2
- 201000010653 vesiculitis Diseases 0.000 description 2
- 108010047303 von Willebrand Factor Proteins 0.000 description 2
- 102100036537 von Willebrand factor Human genes 0.000 description 2
- 229960001134 von willebrand factor Drugs 0.000 description 2
- 210000005253 yeast cell Anatomy 0.000 description 2
- 229940055760 yervoy Drugs 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- KAWIOCMUARENDQ-UHFFFAOYSA-N 2-(4-chlorophenyl)sulfanyl-n-(4-pyridin-2-yl-1,3-thiazol-2-yl)acetamide Chemical compound C1=CC(Cl)=CC=C1SCC(=O)NC1=NC(C=2N=CC=CC=2)=CS1 KAWIOCMUARENDQ-UHFFFAOYSA-N 0.000 description 1
- JODKFOVZURLVTG-UHFFFAOYSA-N 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone Chemical compound [O-][N+](=O)C1([N+]([O-])=O)CN(C(=O)CBr)C1 JODKFOVZURLVTG-UHFFFAOYSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 102000002627 4-1BB Ligand Human genes 0.000 description 1
- 108010082808 4-1BB Ligand Proteins 0.000 description 1
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 1
- 229940125979 ALX148 Drugs 0.000 description 1
- 108700001691 ALX148 Proteins 0.000 description 1
- 229940125554 ASP-8374 Drugs 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 235000016626 Agrimonia eupatoria Nutrition 0.000 description 1
- 108090000672 Annexin A5 Proteins 0.000 description 1
- 102000004121 Annexin A5 Human genes 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000512259 Ascophyllum nodosum Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 235000000832 Ayote Nutrition 0.000 description 1
- 229940125556 BGB-A1217 Drugs 0.000 description 1
- 229940125565 BMS-986016 Drugs 0.000 description 1
- 229940125557 BMS-986207 Drugs 0.000 description 1
- 241000218495 Bactrocera correcta Species 0.000 description 1
- 102100028239 Basal cell adhesion molecule Human genes 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 241001536303 Botryococcus braunii Species 0.000 description 1
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 102100032912 CD44 antigen Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 241000195597 Chlamydomonas reinhardtii Species 0.000 description 1
- 244000249214 Chlorella pyrenoidosa Species 0.000 description 1
- 235000007091 Chlorella pyrenoidosa Nutrition 0.000 description 1
- 239000004155 Chlorine dioxide Substances 0.000 description 1
- 241000243321 Cnidaria Species 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 240000004244 Cucurbita moschata Species 0.000 description 1
- 235000009854 Cucurbita moschata Nutrition 0.000 description 1
- 235000009804 Cucurbita pepo subsp pepo Nutrition 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 102000010969 Cytokine TWEAK Human genes 0.000 description 1
- 108010037645 Cytokine TWEAK Proteins 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000258955 Echinodermata Species 0.000 description 1
- 108010072589 Ectodysplasins Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102100037241 Endoglin Human genes 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 229940125570 FS118 Drugs 0.000 description 1
- 108010039471 Fas Ligand Protein Proteins 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 210000000712 G cell Anatomy 0.000 description 1
- 101710131437 Gene 39 protein Proteins 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 241000219146 Gossypium Species 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 229920001499 Heparinoid Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000935638 Homo sapiens Basal cell adhesion molecule Proteins 0.000 description 1
- 101000766294 Homo sapiens Branched-chain-amino-acid aminotransferase, mitochondrial Proteins 0.000 description 1
- 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- 101000881679 Homo sapiens Endoglin Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101001002470 Homo sapiens Interferon lambda-1 Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 1
- 101100370001 Homo sapiens TNFSF14 gene Proteins 0.000 description 1
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 1
- 101000830603 Homo sapiens Tumor necrosis factor ligand superfamily member 11 Proteins 0.000 description 1
- 101000764263 Homo sapiens Tumor necrosis factor ligand superfamily member 4 Proteins 0.000 description 1
- 101000622304 Homo sapiens Vascular cell adhesion protein 1 Proteins 0.000 description 1
- 102100025306 Integrin alpha-IIb Human genes 0.000 description 1
- 101710149643 Integrin alpha-IIb Proteins 0.000 description 1
- 108010008212 Integrin alpha4beta1 Proteins 0.000 description 1
- 102100020990 Interferon lambda-1 Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108010057281 Lipocalin 1 Proteins 0.000 description 1
- 102000003752 Lipocalin 1 Human genes 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 241000195947 Lycopodium Species 0.000 description 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
- 102000003959 Lymphotoxin-beta Human genes 0.000 description 1
- 108090000362 Lymphotoxin-beta Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000218922 Magnoliophyta Species 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 241000196323 Marchantiophyta Species 0.000 description 1
- 206010027145 Melanocytic naevus Diseases 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101000597780 Mus musculus Tumor necrosis factor ligand superfamily member 18 Proteins 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 230000006051 NK cell activation Effects 0.000 description 1
- 241001250129 Nannochloropsis gaditana Species 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 208000003788 Neoplasm Micrometastasis Diseases 0.000 description 1
- 208000007256 Nevus Diseases 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 108010035766 P-Selectin Proteins 0.000 description 1
- 102100023472 P-selectin Human genes 0.000 description 1
- 102100037601 P2X purinoceptor 4 Human genes 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108010047320 Pepsinogen A Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000985694 Polypodiopsida Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 108010080192 Purinergic Receptors Proteins 0.000 description 1
- 229940125566 REGN3767 Drugs 0.000 description 1
- 108090000783 Renin Proteins 0.000 description 1
- 102100028255 Renin Human genes 0.000 description 1
- 241000702263 Reovirus sp. Species 0.000 description 1
- 101710176276 SSB protein Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- 241000593524 Sargassum patens Species 0.000 description 1
- 241000710961 Semliki Forest virus Species 0.000 description 1
- 241001632234 Senecavirus Species 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229940125564 Sym022 Drugs 0.000 description 1
- 230000006043 T cell recruitment Effects 0.000 description 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 1
- 229940125567 TSR-033 Drugs 0.000 description 1
- 102000036693 Thrombopoietin Human genes 0.000 description 1
- 108010041111 Thrombopoietin Proteins 0.000 description 1
- 102000003938 Thromboxane Receptors Human genes 0.000 description 1
- 108090000300 Thromboxane Receptors Proteins 0.000 description 1
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 1
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 1
- 102000056172 Transforming growth factor beta-3 Human genes 0.000 description 1
- 108090000097 Transforming growth factor beta-3 Proteins 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 101710097160 Tumor necrosis factor ligand superfamily member 10 Proteins 0.000 description 1
- 101710097161 Tumor necrosis factor ligand superfamily member 11 Proteins 0.000 description 1
- 102100026890 Tumor necrosis factor ligand superfamily member 4 Human genes 0.000 description 1
- 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 1
- 208000035896 Twin-reversed arterial perfusion sequence Diseases 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 1
- 101150097457 Vcam1 gene Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 229950001573 abemaciclib Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 210000001132 alveolar macrophage Anatomy 0.000 description 1
- 210000001053 ameloblast Anatomy 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002001 anti-metastasis Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000013059 antihormonal agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 1
- 210000004396 apud cell Anatomy 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 229960003852 atezolizumab Drugs 0.000 description 1
- 210000002453 autonomic neuron Anatomy 0.000 description 1
- 210000004666 bacterial spore Anatomy 0.000 description 1
- 210000004082 barrier epithelial cell Anatomy 0.000 description 1
- 210000002947 bartholin's gland Anatomy 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 229950007843 bavituximab Drugs 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 238000005415 bioluminescence Methods 0.000 description 1
- 230000029918 bioluminescence Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000465 brunner gland Anatomy 0.000 description 1
- 210000002533 bulbourethral gland Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229950007712 camrelizumab Drugs 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 229960004424 carbon dioxide Drugs 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 210000003321 cartilage cell Anatomy 0.000 description 1
- 229920006317 cationic polymer Polymers 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000005859 cell recognition Effects 0.000 description 1
- 230000005887 cellular phagocytosis Effects 0.000 description 1
- 210000000250 cementoblast Anatomy 0.000 description 1
- 229940121420 cemiplimab Drugs 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 210000004691 chief cell of stomach Anatomy 0.000 description 1
- 235000019398 chlorine dioxide Nutrition 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 210000000254 ciliated cell Anatomy 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 108010047295 complement receptors Proteins 0.000 description 1
- 102000006834 complement receptors Human genes 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 210000000555 contractile cell Anatomy 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 210000004246 corpus luteum Anatomy 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- JVHIPYJQMFNCEK-UHFFFAOYSA-N cytochalasin Natural products N1C(=O)C2(C(C=CC(C)CC(C)CC=C3)OC(C)=O)C3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 JVHIPYJQMFNCEK-UHFFFAOYSA-N 0.000 description 1
- ZMAODHOXRBLOQO-UHFFFAOYSA-N cytochalasin-A Natural products N1C(=O)C23OC(=O)C=CC(=O)CCCC(C)CC=CC3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 ZMAODHOXRBLOQO-UHFFFAOYSA-N 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 229960003603 decitabine Drugs 0.000 description 1
- 229950008937 defactinib Drugs 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 229950004647 emactuzumab Drugs 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 229950004270 enoblituzumab Drugs 0.000 description 1
- 210000004188 enterochromaffin-like cell Anatomy 0.000 description 1
- 210000003158 enteroendocrine cell Anatomy 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 1
- 210000003426 epidermal langerhans cell Anatomy 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 229940115924 etigilimab Drugs 0.000 description 1
- 210000003499 exocrine gland Anatomy 0.000 description 1
- 210000001808 exosome Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 125000004030 farnesyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229940124981 favezelimab Drugs 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 210000004905 finger nail Anatomy 0.000 description 1
- 210000004904 fingernail bed Anatomy 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 210000002618 gastric chief cell Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 210000003772 granulosa lutein cell Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 239000002554 heparinoid Substances 0.000 description 1
- 229940025770 heparinoids Drugs 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 208000002557 hidradenitis Diseases 0.000 description 1
- 238000000703 high-speed centrifugation Methods 0.000 description 1
- 229940121569 ieramilimab Drugs 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910001867 inorganic solvent Inorganic materials 0.000 description 1
- 239000003049 inorganic solvent Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 210000002570 interstitial cell Anatomy 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 210000001865 kupffer cell Anatomy 0.000 description 1
- 229940057958 lacnotuzumab Drugs 0.000 description 1
- 210000004561 lacrimal apparatus Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000001381 lactotroph Effects 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 210000003644 lens cell Anatomy 0.000 description 1
- 210000002332 leydig cell Anatomy 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 235000009973 maize Nutrition 0.000 description 1
- 238000005621 mannosylation reaction Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 240000004308 marijuana Species 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229950009580 merestinib Drugs 0.000 description 1
- 229960005558 mertansine Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- 230000002025 microglial effect Effects 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 210000000110 microvilli Anatomy 0.000 description 1
- 238000010232 migration assay Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 229950001907 monalizumab Drugs 0.000 description 1
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 210000004985 myeloid-derived suppressor cell Anatomy 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- QHADVLVFMKEIIP-UHFFFAOYSA-N n-[3-fluoro-4-[1-methyl-6-(1h-pyrazol-4-yl)indazol-5-yl]oxyphenyl]-1-(4-fluorophenyl)-6-methyl-2-oxopyridine-3-carboxamide Chemical compound O=C1N(C=2C=CC(F)=CC=2)C(C)=CC=C1C(=O)NC(C=C1F)=CC=C1OC1=CC=2C=NN(C)C=2C=C1C=1C=NNC=1 QHADVLVFMKEIIP-UHFFFAOYSA-N 0.000 description 1
- UZWDCWONPYILKI-UHFFFAOYSA-N n-[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine Chemical compound C1CN(CC)CCN1CC(C=N1)=CC=C1NC1=NC=C(F)C(C=2C=C3N(C(C)C)C(C)=NC3=C(F)C=2)=N1 UZWDCWONPYILKI-UHFFFAOYSA-N 0.000 description 1
- FWLMVFUGMHIOAA-UHFFFAOYSA-N n-methyl-4-[[4-[[3-[methyl(methylsulfonyl)amino]pyrazin-2-yl]methylamino]-5-(trifluoromethyl)pyrimidin-2-yl]amino]benzamide Chemical compound C1=CC(C(=O)NC)=CC=C1NC1=NC=C(C(F)(F)F)C(NCC=2C(=NC=CN=2)N(C)S(C)(=O)=O)=N1 FWLMVFUGMHIOAA-UHFFFAOYSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 229950011068 niraparib Drugs 0.000 description 1
- PCHKPVIQAHNQLW-CQSZACIVSA-N niraparib Chemical compound N1=C2C(C(=O)N)=CC=CC2=CN1C(C=C1)=CC=C1[C@@H]1CCCNC1 PCHKPVIQAHNQLW-CQSZACIVSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 210000001915 nurse cell Anatomy 0.000 description 1
- 210000001706 olfactory mucosa Anatomy 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 229940121476 omburtamab Drugs 0.000 description 1
- 230000000174 oncolytic effect Effects 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 210000002380 oogonia Anatomy 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 210000004409 osteocyte Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 210000000277 pancreatic duct Anatomy 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 210000002990 parathyroid gland Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940043138 pentosan polysulfate Drugs 0.000 description 1
- 229940121593 pepinemab Drugs 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 210000003668 pericyte Anatomy 0.000 description 1
- 210000002856 peripheral neuron Anatomy 0.000 description 1
- JGWRKYUXBBNENE-UHFFFAOYSA-N pexidartinib Chemical compound C1=NC(C(F)(F)F)=CC=C1CNC(N=C1)=CC=C1CC1=CNC2=NC=C(Cl)C=C12 JGWRKYUXBBNENE-UHFFFAOYSA-N 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 210000004694 pigment cell Anatomy 0.000 description 1
- 210000001127 pigmented epithelial cell Anatomy 0.000 description 1
- 210000000793 pinealocyte Anatomy 0.000 description 1
- 210000004043 pneumocyte Anatomy 0.000 description 1
- 210000000557 podocyte Anatomy 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229930001119 polyketide Natural products 0.000 description 1
- 150000003881 polyketide derivatives Chemical class 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 235000012015 potatoes Nutrition 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000001141 propulsive effect Effects 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 102000017953 prostanoid receptors Human genes 0.000 description 1
- 108050007059 prostanoid receptors Proteins 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 210000000512 proximal kidney tubule Anatomy 0.000 description 1
- 235000015136 pumpkin Nutrition 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 229960002633 ramucirumab Drugs 0.000 description 1
- 108091006084 receptor activators Proteins 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 229940121484 relatlimab Drugs 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 150000003839 salts Chemical group 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- 210000003728 serous cell Anatomy 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 238000012174 single-cell RNA sequencing Methods 0.000 description 1
- 210000002363 skeletal muscle cell Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000001622 small lutein cell Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 210000002325 somatostatin-secreting cell Anatomy 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 229950007213 spartalizumab Drugs 0.000 description 1
- 210000004336 spermatogonium Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 210000004500 stellate cell Anatomy 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 210000000352 storage cell Anatomy 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229950008461 talimogene laherparepvec Drugs 0.000 description 1
- 210000001779 taste bud Anatomy 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229940066453 tecentriq Drugs 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000003684 theca cell Anatomy 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 229960004906 thiomersal Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 229950007133 tiragolumab Drugs 0.000 description 1
- 210000004906 toe nail Anatomy 0.000 description 1
- 210000000515 tooth Anatomy 0.000 description 1
- 210000003014 totipotent stem cell Anatomy 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 108010075758 trebananib Proteins 0.000 description 1
- 229950001210 trebananib Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- 210000002014 trichocyte Anatomy 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 239000000107 tumor biomarker Substances 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 230000009452 underexpressoin Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 229950005972 urelumab Drugs 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 229950001067 varlilumab Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 210000001849 von ebner gland Anatomy 0.000 description 1
- 229940121351 vopratelimab Drugs 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Definitions
- the IL-12 polypeptide comprises a membrane-bound IL-12 polypeptide. In some embodiments, the IL-12 polypeptide is complexed to the cell surface of the enucleated cell. In some embodiments, the enucleated cell induces an endogenous immune response at a site associated with the disease or condition of the subject. In some embodiments, the method further comprises treating the WSGR Docket No.53712-720.601 disease or condition of the subject, at least in part, by inducing an endogenous immune response in the subject. In some embodiments, the site associated with the disease or condition comprises a microenvironment. In some embodiments, the microenvironment is a tumor microenvironment.
- a method for inducing endogenous immune response in a subject comprising: administering to the subject an enucleated cell comprising (a) an exogenous mRNA encoding a cytokine polypeptide; and (b) one or more organelles for expressing the cytokine polypeptide on a cell surface of the enucleated cell, wherein the cytokine polypeptide induces the endogenous immune response in the subject.
- the cytokine polypeptide comprises a membrane-bound cytokine polypeptide.
- the cytokine polypeptide is complexed to the cell surface of the enucleated cell.
- the enucleated cell induces the endogenous immune response at a microenvironment.
- the microenvironment is a tumor microenvironment.
- the microenvironment is a lymphatic microenvironment, a hepatic microenvironment, a spleen microenvironment, a pancreatic WSGR Docket No.53712-720.601 microenvironment, an epidermis microenvironment, or a combination thereof.
- the enucleated cell induces the endogenous immune response in proximity of a cell.
- the cell is a cancer cell.
- the cell is an immune cell.
- the immune cell is a leukocyte.
- the cytokine polypeptide is expressed on a cell surface of the enucleated cell for at least 24 hours. In some embodiments, the cytokine polypeptide is complexed with the enucleated cell for the at least 24 hours. In some embodiments, the cytokine polypeptide is not secreted by the enucleated cell. In some embodiments, the cytokine polypeptide is not delivered to the microenvironment. In some embodiments, the cytokine polypeptide is not delivered to the cell. In some embodiments, the cytokine polypeptide comprises a full-length cytokine or antigen binding fragment thereof of the cytokine.
- the cytokine polypeptide encoded by the exogenous mRNA results in a decreased toxicity in the subject compared to a toxicity caused by direct delivery of the cytokine polypeptide.
- the cytokine polypeptide comprises an interleukin polypeptide.
- the interleukin polypeptide is an IL-12 polypeptide.
- the cytokine polypeptide comprises an interleukin antibody or antigen binding fragment thereof.
- the cytokine polypeptide comprises IL-12 or antigen binding fragment thereof.
- the endogenous immune response comprises an innate immune response or adaptive immune response.
- the enucleated cell further comprises an immune checkpoint inhibitor.
- the enucleated cell expresses an abundance of the cytokine polypeptide that is at least 0.1 fold, at least 0.2 fold, at least 0.5 fold, at least 1.0 fold, at least 2.0 fold, or at least 5.0 fold higher than the enucleated cell expressing an abundance of a comparable naturally-occurring cytokine polypeptide.
- the abundance of the cytokine polypeptide and the abundance of the comparable naturally-occurring cytokine polypeptide is determined by FACS.
- the cytokine polypeptide is not secreted by the enucleated cell.
- the cytokine polypeptide comprises an interleukin polypeptide.
- the interleukin polypeptide is IL-12 polypeptide.
- the enucleated cell further comprises an immune checkpoint inhibitor.
- the immune checkpoint inhibitor comprises a PD-1 inhibitor, a PD-L1 inhibitor, a TIM-3 inhibitor, a LAG-3 inhibitor, a TIGIT inhibitor, a CD47 inhibitor, a B7 inhibitor, a CD 137 inhibitor, a CTLA-4 inhibitor, or any combination thereof.
- the immune checkpoint inhibitor comprises the PD-1 inhibitor.
- the immune checkpoint inhibitor is encoded by a second exogenous mRNA in the enucleated cell.
- the enucleated cell is depleted of an immune recognition molecule.
- the immune recognition molecule comprises HLA antigen, proteoglycan, sugar moiety, embryonic antigen, or any combination thereof.
- the enucleated cell comprises a targeting moiety.
- the targeting moiety comprises CXCR2, CCR2, PSGL- 1, or a combination thereof.
- the composition further comprises an immune checkpoint inhibitor.
- the immune checkpoint inhibitor comprises a PD-1 inhibitor, a PD-L1 inhibitor, a TIM-3 inhibitor, a LAG-3 inhibitor, a TIGIT inhibitor, a CD47 inhibitor, a B7 inhibitor, a CD 137 inhibitor, a CTLA-4 inhibitor, or any combination thereof.
- the immune checkpoint inhibitor comprises the PD- 1 inhibitor. In some embodiments, the immune checkpoint inhibitor is encoded by a second exogenous mRNA in the enucleated cell. In some embodiments, the immune checkpoint inhibitor is encoded by a second enucleated cell.
- Fig.1B illustrates mesenchymal stem cells (MSCs), MSC-derived enucleated cells transfected with IL-12 mRNA (MSC IL-12 and Enucleated cell IL-12 respectively), or conditioned medium (CM) collected at the indicated time points.
- Fig.1C illustrates CM from cells/enucleated cells as shown in Fig.1B assessed in mouse splenocytes for the activation of the phosphorylated/activated form of Stat4 (p-Stat4) by western blot.
- Fig.1D illustrates a schematic for using the enucleated cell to treat a triple negative breast cancer (TNBC) mouse model.
- TNBC triple negative breast cancer
- Fig.1E illustrates measurements of IL-12 secreted by the enucleated cell within tumor microenvironment.
- Fig.1F illustrates serum IL-12 measurement.
- Fig.1G illustrates measurements of IL-12 mediated inflammatory biomarkers.
- Fig.1H illustrates mice bearing SQ E0771 tumors injected with a total of three doses of either PBS, MSCs secreting IL-12, or CA-IL-12.
- Fig.1I illustrates FACS analysis for detecting leukocyte activation.
- Fig.2A illustrates a schematic of enucleated cell that secreted IL-12 alone or in combination with the checkpoint inhibitor anti-PD-1 antibody for treating cancer mouse model.
- Fig.2B illustrates a survival curve for animals injected as described in Fig.2A.
- Fig.2C illustrates a graph of tumor size over time post-injection.
- Fig.2D illustrates a graph of fold change in animal weight during the treatment phase of the survival experiments shown in Fig.2B.
- Fig.3B illustrates Boyden Chamber migration assay showing mesenchymal stem cells or enucleated cells engineered for expressing CCR2, CXCR4, and leukocyte adhesion molecule (PSGL-1; termed CCP MSCs or CCP enucleated cells respectively) for robustly homing towards CCL2, SDF-1a, and EO771 conditioned medium relative to a no-chemoattractant negative control.
- PSGL-1 leukocyte adhesion molecule
- Fig.4B illustrates homing of the enucleated cells to tumors.
- Fig.4C illustrates FACS for determining the abundance of enucleated cells homed to tumors.
- Fig.5A illustrate infiltration of the enucleated cell infiltration.
- Fig.5B illustrates optical sectioning and 3D reconstruction of the center of macrometastasis revealed that clusters of CCP enucleated cells.
- Fig.5C illustrates single channel acquisition of DAPI stained sections showing normal lung architecture and no tumor mass.
- Fig.8A illustrates an exemplary design of the enucleated cell expressing cell membrane tethered IL-12.
- Fig.8B illustrates non-limiting example of a vector map of a vector encoding IL-12.
- Fig.8C illustrates engineering and screening for the enucleated cell expressing membrane-bound scIL-12.
- WSGR Docket No.53712-720.601 illustrates an exemplary mechanism of immune cell activation by CA-scIL-12.
- Fig.9A illustrates MSCs or enucleated cells engineered with or without scIL-12 that were co-cultured with primary murine splenocytes and concanavalin A for 48 hours.
- Fig.9B illustrates enucleated cells (1 x10 6 ) engineered to secrete IL-12 (CA-IL-12).
- Fig.11A illustrates a schematic for engineering the hTERT-MSC for expression both scIL-12 and IL-15R ⁇ and the subsequent enucleation of the hTERT-MSC.
- Fig.11B illustrates hTERT MSCs infected with two lentiviruses encoding constructs for either scIL-12 or IL-15R ⁇ . Following drug selection, cells were FACS sorted for single cell clones. Clone 4 was enucleated to generate enucleated cells expressing both scIL-12 and IL- 15R ⁇ , and receptor expression was analyzed by FACS at the indicated time points.
- Fig.11C illustrates functionality of expressing membrane-bound IL-12, IL-15, or a combination of both IL-12 and IL-15.
- Fig.12A illustrates biodistribution of the enucleated cells by bioluminescence.
- Fig.12B illustrates quantification of biodistribution of the enucleated cells of Fig.12A.
- Fig.13A illustrates increased homing of the enucleated cell described herein compared to nucleated mesenchymal stem cell (MSC).
- MSC nucleated mesenchymal stem cell
- Fig.13B illustrates quantification of homing of the enucleated cell of Fig.13A.
- Fig.14A illustrates homing of the enucleated cell based on increased chemoattractants in the TNBC tumor metastatic sites.
- Fig.14B illustrates dot plots of expression of Cxcl (Top) and Ccl (Bottom) chemokines within Vcam1-positive cells in Cluster 1 confirming Cxcl12 (encoding SDF-1 ⁇ ) and Ccl2 were the highest expressed Cxcl and Ccl chemokines, respectively.
- the active agent may be a protein.
- the active agent may be an antibody, antigen, or a fragment of said antibody or antigen.
- cells comprising mRNA to express a protein, an antibody, an antigen, or portion thereof, and compositions containing such cells.
- the cells are enucleated.
- the protein, antibody, antigen, or portion thereof is a therapeutic agent.
- the enucleated cell is obtained or derived from a nucleated cell (e.g., a parent cell). In some aspects, the enucleated cell comprises a transmembrane moiety. In some embodiments, the enucleated cells comprises a targeting moiety. In some embodiments, the enucleated cell comprises a therapeutic agent. In some embodiments, the enucleated cell comprises a protein. In some embodiments, the enucleated cell comprises a cytokine. In some WSGR Docket No.53712-720.601 embodiments, the enucleated cell comprises an antibody or antigen binding fragment thereof or a single-domain antibody or an antigen binding fragment thereof.
- an enucleated cell may be derived from an adult stem cell, a mesenchymal stromal cell (MSC), a natural killer (NK) cell, a macrophage, a myoblast, a neutrophil, endothelial cell, endothelial precursor cell, and/or a fibroblast.
- an enucleated cell is derived from a mesenchymal stromal cell.
- the enucleated cell is derived from an inducible pluripotent stem cell (iPSC).
- the parent cell is derived from a cell is immortalized using suitable methods.
- parent cell is immortalized by expressing human telomerase reverse transcriptase (hTERT), an oncogene, or a viral gene such as simian virus 40 (SV40).
- hTERT human telomerase reverse transcriptase
- SV40 viral gene
- the cytoplast is derived from a parent cell using suitable methods provided in United States Patent No.10,927,349, which is hereby incorporated by reference in its entirety.
- the enucleated cell retains one or more intracellular organelles for synthesis of an exogenous protein.
- the enucleated cell retains one or more intracellular organelles for synthesis of an exogenous cytokine.
- the enucleated cell does not require differentiation of the parent cell.
- the parent cell containing a nucleus is engineered to express the single-domain antibody or antigen-binding fragment thereof, therapeutic agent, transmembrane moiety, immune-evading moiety, and/or targeting moiety described herein; and subsequently, the nucleus of the parent cell is removed.
- the parent cell containing the nucleus is enucleated, and the enucleated cell is engineered to express single-domain antibody or antigen-binding fragment thereof, therapeutic agent, transmembrane moiety, immune-evading moiety, and/or targeting moiety described herein.
- the parent cell is engineered to express one or more of the biomolecules above (e.g., immune-evading moiety and/or targeting moiety), and the resulting enucleated cell (e.g., already expressing the immune- evading moiety and/or targeting moiety) is further engineered to express a second of the biomolecules above (e.g., a therapeutic agent).
- the biomolecules above e.g., immune-evading moiety and/or targeting moiety
- a second of the biomolecules above e.g., a therapeutic agent
- the enucleated cells of the present WSGR Docket No.53712-720.601 disclosure can be extensively engineered prior to enucleation, stored for long periods of time as needed (through for e.g., lyophilization, cryohibernation, cryopreservation), and quickly engineered to express a therapeutic agent closer to the time of need.
- the cell can originate from any organism having one or more cells.
- Non-limiting examples of cells include: a prokaryotic cell, eukaryotic cell, a bacterial cell, an archaeal cell, a cell of a single-cell eukaryotic organism, a protozoa cell, a cell from a plant (e.g.
- algal cells from plant crops, fruits, vegetables, grains, soy bean, corn, maize, wheat, seeds, tomatoes, rice, cassava, sugarcane, pumpkin, hay, potatoes, cotton, cannabis, tobacco, flowering plants, conifers, gymnosperms, ferns, clubmosses, hornworts, liverworts, mosses), an algal cell, (e.g., Botryococcus braunii, Chlamydomonas reinhardtii, Nannochloropsis gaditana, Chlorella pyrenoidosa, Sargassum patens C. Agardh, and the like), seaweeds (e.g.
- a fungal cell e.g., a yeast cell, a cell from a mushroom
- an animal cell e.g. fruit fly, cnidarian, echinoderm, nematode, etc.
- a cell from a vertebrate animal e.g., fish, amphibian, reptile, bird, mammal
- a cell from a mammal e.g., a pig, a cow, a goat, a sheep, a rodent, a rat, a mouse, a non-human primate, a human, etc.
- a mammal e.g., a pig, a cow, a goat, a sheep, a rodent, a rat, a mouse, a non-human primate, a human, etc.
- a cell is not originating from a natural organism (e.g., a cell can be a synthetically made, sometimes termed an artificial cell).
- the cell is a somatic cell.
- the cell is a stem cell or a progenitor cell.
- the cell is a mesenchymal stem or progenitor cell.
- the cell is a hematopoietic stem or progenitor cell.
- the cell is a muscle cell, a skin cell, a blood cell, or an immune cell.
- lymphoid cells such as B cell, T cell (Cytotoxic T cell, Natural Killer T cell, Regulatory T cell, T helper cell), Natural killer cell, cytokine induced killer (CIK) cells; myeloid cells such as granulocytes (Basophil granulocyte, Eosinophil granulocyte, Neutrophil granulocyte/Hypersegmented neutrophil), Monocyte/Macrophage, Red blood cell (Reticulocyte), Mast cell, Thrombocyte/Megakaryocyte, Dendritic cell; cells from the endocrine system, including thyroid (Thyroid epithelial cell, Parafollicular cell), parathyroid (Parathyroid chief cell, Oxyphil cell), adrenal (Chromaffin cell), pineal (Pinealocyte) cells; cells of the nervous system, including glial cells (Astrocyte, Microglia), Magnocellular neurosecretory cell, Stellate cell, Boettcher cell, and pituitary (Gonadotrope
- the nucleated cell is an immune cell (e.g., a lymphocyte (e.g., a T cell, a B cell), a macrophage, a natural killer cell, a neutrophil, a mast cell, a basophil, a dendritic cell, a monocyte, a myeloid- derived suppressor cell, an eosinophil).
- the nucleated cell is a phagocyte or a leukocyte.
- the nucleated cell is a stem cell (e.g., an adult stem cell (e.g., a hematopoietic stem cell, a mammary stem cell, an intestinal stem cell, mesenchymal stem cell, an endothelial stem cell, a neural stem cell, an olfactory adult stem cell, a neural crest stem cell, a testicular cell), an embryonic stem cell, an inducible pluripotent stem cell (iPS)).
- the nucleated cell is a progenitor cell.
- the nucleated cell is from a cell line.
- the nucleated cell is a suspension cell.
- the nucleated cell is an adherent cell.
- the nucleated cell is a cell that has been immortalized by expression of an oncogene.
- the nucleated cell is immortalized by the expression of human telomerase reverse transcriptase (hTERT) or any oncogene.
- the nucleated cell is immortalized by the expression of a viral gene such as simian virus 40 (SV40).
- the nucleated cell is a patient or subject derived cell (e.g., an autologous patient-derived cell, or an allogenic patient-derived cell).
- the enucleated cell is derived from an immune cell.
- the enucleated cell is derived from a natural killer (NK) cell, a neutrophil, a macrophage, a lymphocyte, a fibroblast, an adult stem cell (e.g., hematopoietic stem cell, a mammary stem cell, an intestinal stem cell, a mesenchymal stem cell, a mesenchymal stromal cell, an endothelial stem cell, a neural stem cell, an olfactory adult stem cell, a neural crest stem cell, a skin stem cell, or a testicular cell), a mast cell, a basophil, an eosinophil, an endothelial cell, an endothelial cell precursor cell, or an inducible pluripotent stem cell.
- NK natural killer
- neutrophil e.g., hematopoietic stem cell, a mammary stem cell, an intestinal stem cell, a mesenchy
- the parent cell is not an erythrocyte or erythroid precursor cell. In some embodiments, the parent cell is a platelet cell. In some embodiments, the parent cell is not an endothelial cell. In some embodiments, the parent cell is not an endothelial precursor cell. In some embodiments, the enucleated cell is not an erythrocyte or erythroid precursor cell. In some embodiments, the enucleated cell is not a platelet cell. In some embodiments, the enucleated cell is not an endothelial cell. In some embodiments, the enucleated cell is not an endothelial precursor cell.
- the enucleated cell does not express complement receptor one (CR1). In some embodiments, the enucleated cell does not express CD44. In some embodiments, the enucleated cell does not express VLA-4. In some embodiments, the enucleated cell does not express BCAM. In some embodiments, the enucleated cell does not express ICAM. In some embodiments, the enucleated cell does not express a receptor for collagen. In some embodiments, the enucleated cell does not express a receptor for thrombopoietin. In some embodiments, the enucleated cell does not express a receptor for collagen.
- CR1 complement receptor one
- the enucleated cell does not express CD44. In some embodiments, the enucleated cell does not express VLA-4. In some embodiments, the enucleated cell does not express BCAM. In some embodiments, the enucleated cell does not express ICAM. In some embodiments, the enucleated cell does not express
- the enucleated cell does not express a receptor for von Willebrand factor (VWF). In some embodiments, the enucleated cell does not express a receptor for fibrinogen. In some embodiments, the enucleated cell does not express GP1b-IX-V receptor. In some embodiments, the enucleated cell does not express GPIIb/IIIa receptor. In some embodiments, the enucleated cell does not express prostanoid receptor. In some embodiments, the enucleated cell does not express purinergic receptor. In some embodiments, the enucleated cell does not express thromboxane receptor.
- VWF von Willebrand factor
- the parent cell is not an endothelial precursor cell.
- a parent cell may be treated with cytochalasin to soften the cortical actin cytoskeleton.
- the nucleus may then physically extracted from the cell body by high-speed centrifugation in gradients of Ficoll to generate an enucleated cell. Because enucleate cells and intact nucleated cells sediment to different layers in the Ficoll gradient, enucleated cells may be easily isolated and prepared for therapeutic purposes or fusion to other cells (nucleated or enucleated).
- the enucleation process is clinically scalable to process tens of millions of cells.
- enucleated cells may be used as a disease-homing vehicle to express clinically relevant cargos/payloads to treat various diseases.
- the enucleated cells described herein retain one or more intracellular organelles that are endogenous to the parent cell. In some embodiments, all of the one or more intracellular organelles are retained. In some embodiments, fewer than all of the one or more intracellular organelles are retained. In some embodiments, the Golgi apparatus and/or the endoplasmic reticulum are retained, which are involved in protein synthesis and secretion.
- Enucleated cells may be smaller than their nucleated counterparts (e.g., the nucleated parent cells), and for this reason may migrate better through small openings in the vasculature and tissue parenchyma.
- removing the large dense nucleus alleviates a major physical barrier allowing the cell to move freely through small openings in the vessels and tissue parenchyma.
- an enucleated cell has improved bio-distribution in the body and movement into target tissues.
- an enucleated cell comprises at least 1 ⁇ m in diameter. In some embodiments, an enucleated cell is greater than 1 ⁇ m in diameter.
- the amount of the active agent is about 2.00 to about 10.00 fold increase over endogenous amount of the active agent. n some embodiments, the amount of the active agent is about 2.00 to about 15.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 2.00 to about 20.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 2.00 to about 25.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 2.00 to about 30.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 2.00 to about 35.00 fold increase over endogenous amount of the active agent.
- the amount of the active agent is about 15.00 to about 90.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 15.00 to about 95.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 15.00 to about 100.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 15.00 to about 105.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 15.00 to about 110.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 15.00 to about 115.00 fold increase over endogenous amount of the active agent.
- the amount of the active agent is about 15.00 to about 150.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 20.00 to about 25.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 20.00 to about 30.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 20.00 to about 35.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 20.00 to about 40.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 20.00 to about 45.00 fold increase over endogenous amount of the active agent.
- the amount of the active agent is about 25.00 to about 95.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 25.00 to about 100.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 25.00 to about 105.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 25.00 to about 110.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 25.00 to about 115.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 25.00 to about 120.00 fold increase over endogenous amount of the active agent.
- the amount of the active agent is about 50.00 to about 60.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 50.00 to about 65.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 50.00 to about 70.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 50.00 to about 75.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 50.00 to about 80.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 50.00 to about 85.00 fold increase over endogenous amount of the active agent.
- the amount of the active agent is about 50.00 to about 90.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 50.00 to about 95.00 fold increase WSGR Docket No.53712-720.601 over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 50.00 to about 100.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 50.00 to about 105.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 50.00 to about 110.00 fold increase over endogenous amount of the active agent.
- the amount of the active agent is about 60.00 to about 75.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 60.00 to about 80.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 60.00 to about 85.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 60.00 to about 90.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 60.00 to about 95.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 60.00 to about 100.00 fold increase over endogenous amount of the active agent.
- the amount of the active agent is about 70.00 to about 85.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 70.00 to about 90.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 70.00 to about 95.00 fold increase over endogenous amount of the active WSGR Docket No.53712-720.601 agent. In some embodiments, the amount of the active agent is about 70.00 to about 100.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 70.00 to about 105.00 fold increase over endogenous amount of the active agent.
- the amount of the active agent is about 70.00 to about 110.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 70.00 to about 115.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 70.00 to about 120.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 70.00 to about 125.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 70.00 to about 130.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 70.00 to about 135.00 fold increase over endogenous amount of the active agent.
- the amount of the active agent is about 75.00 to about 95.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 75.00 to about 100.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 75.00 to about 105.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 75.00 to about 110.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 75.00 to about 115.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 75.00 to about 120.00 fold increase over endogenous amount of the active agent.
- the amount of the active agent is about 75.00 to about 125.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 75.00 to about 130.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 75.00 to about 135.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the WSGR Docket No.53712-720.601 active agent is about 75.00 to about 140.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 75.00 to about 145.00 fold increase over endogenous amount of the active agent.
- the amount of the active agent is about 75.00 to about 150.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 80.00 to about 85.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 80.00 to about 90.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 80.00 to about 95.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 80.00 to about 100.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 80.00 to about 105.00 fold increase over endogenous amount of the active agent.
- the amount of the active agent is about 80.00 to about 110.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 80.00 to about 115.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 80.00 to about 120.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 80.00 to about 125.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 80.00 to about 130.00 fold increase over endogenous amount of the active agent.
- the amount of the active agent is about 80.00 to about 135.00. In some embodiments, the amount of the active agent is about 80.00 to about 140.00.In some embodiments, the amount of the active agent is about 80.00 to about 145.00.In some embodiments, the amount of the active agent is about 80.00 to about 150.00.In some embodiments, the amount of the active agent is about 85.00 to about 90.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 85.00 to about 95.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 85.00 to about 100.00 fold increase over endogenous amount of the active agent.
- the amount of the active agent is about 85.00 to about 105.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 85.00 to about 110.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 85.00 to about 115.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 85.00 to about 120.00 fold increase over endogenous amount of the active agent.
- the amount of the active agent is about 85.00 to about 125.00. In some embodiments, the amount of the active agent is about 85.00 WSGR Docket No.53712-720.601 to about 130.00.In some embodiments, the amount of the active agent is about 85.00 to about 135.00.In some embodiments, the amount of the active agent is about 85.00 to about 140.00.In some embodiments, the amount of the active agent is about 85.00 to about 145.00.In some embodiments, the amount of the active agent is about 85.00 to about 150.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 90.00 to about 95.00 fold increase over endogenous amount of the active agent.
- the amount of the active agent is about 90.00 to about 100.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 90.00 to about 105.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 90.00 to about 110.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 90.00 to about 115.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 90.00 to about 120.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 90.00 to about 125.00 fold increase over endogenous amount of the active agent.
- the amount of the active agent is about 95.00 to about 105.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 95.00 to about 110.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 95.00 to about 115.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 95.00 to about 120.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 95.00 to about 125.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 95.00 to about 130.00 fold increase over endogenous amount of the active agent.
- the amount of the active agent is about 95.00 to about 135.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is WSGR Docket No.53712-720.601 about 95.00 to about 140.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 95.00 to about 145.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 95.00 to about 150.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 100.00 to about 105.00 fold increase over endogenous amount of the active agent.
- the amount of the active agent is about 100.00 to about 110.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 100.00 to about 115.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 100.00 to about 120.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 100.00 to about 125.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 100.00 to about 130.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 100.00 to about 135.00 fold increase over endogenous amount of the active agent.
- the amount of the active agent is about 100.00 to about 140.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 100.00 to about 145.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 100.00 to about 150.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 105.00 to about 110.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 105.00 to about 115.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 105.00 to about 120.00 fold increase over endogenous amount of the active agent.
- the amount of the active agent is about 105.00 to about 125.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 105.00 to about 130.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 105.00 to about 135.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 105.00 to about 140.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 105.00 to about 145.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 105.00 to about 150.00 fold increase over endogenous amount of the active agent.
- the amount of the active agent is about 110.00 to about 115.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 110.00 to about 120.00 fold increase over WSGR Docket No.53712-720.601 endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 110.00 to about 125.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 110.00 to about 130.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 110.00 to about 135.00 fold increase over endogenous amount of the active agent.
- the amount of the active agent is about 110.00 to about 140.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 110.00 to about 145.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 110.00 to about 150.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 115.00 to about 120.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 115.00 to about 125.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 115.00 to about 130.00 fold increase over endogenous amount of the active agent.
- the amount of the active agent is about 115.00 to about 135.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 115.00 to about 140.00 fold increase over endogenous amount of the active agent. n some embodiments, the amount of the active agent is about 115.00 to about 145.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 115.00 to about 150.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 120.00 to about 125.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 120.00 to about 130.00 fold increase over endogenous amount of the active agent.
- the amount of the active agent is about 125.00 to about 140.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 125.00 to about 145.00 fold increase over endogenous amount of the active agent. In some WSGR Docket No.53712-720.601 embodiments, the amount of the active agent is about 125.00 to about 150.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 130.00 to about 135.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 130.00 to about 140.00 fold increase over endogenous amount of the active agent.
- the amount of the active agent is about 130.00 to about 145.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 130.00 to about 150.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 135.00 to about 140.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 135.00 to about 145.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 135.00 to about 150.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 140.00 to about 145.00 fold increase over endogenous amount of the active agent.
- the amount of the active agent is about 140.00 to about 150.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 145.00 to about 150.00 fold increase over endogenous amount of the active agent. In some embodiments, the amount of the active agent is about 0.10, 0.20, 0.30, 0.40, 0.50, 0.60, 0.70, 0.80, 0.90, 1.0, 1.10, 1.20, 1.30, 1.40, 1.50, 1.60, 1.70, 1.80, 1.90, 2.0, 2.10, 2.20, 2.30, 2.40, 2.50, 2.60, 2.70, 2.80, 2.90, 3.0, 3.10, 3.20, 3.30, 3.40, 3.50, 3.60, 3.70, 3.80, 3.90, 4.0, 5.0, 10.0, 15.0, 20.0, 25.0, 30.0, 35.0, 40.0, 45.0, 50.0, 55.0, 60.0, 65.0, 70.0, 75.0, 80.0, 85.0, 90.0, 95.0, 100.0, 11
- the amount of the active agent is greater than or equal to about 0.10, 0.20, 0.30, 0.40, 0.50, 0.60, 0.70, 0.80, 0.90, 1.0, 1.10, 1.20, 1.30, 1.40, 1.50, 1.60, 1.70, 1.80, 1.90, 2.0, 2.10, 2.20, 2.30, 2.40, 2.50, 2.60, 2.70, 2.80, 2.90, 3.0, 3.10, 3.20, 3.30, 3.40, 3.50, 3.60, 3.70, 3.80, 3.90, 4.0, 5.0, 10.0, 15.0, 20.0, 25.0, 30.0, 35.0, 40.0, 45.0, 50.0, 55.0, 60.0, 65.0, 70.0, 75.0, 80.0, 85.0, 90.0, 95.0, 100.0, 115.0, 120.0, 125.0, 130.0, 135.0, 140.0, 145.0, 150.0 fold increase over endogenous amount of the active agent in an otherwise identical cell or a nucleated parent cell.
- the amount of the active agent is less than or equal to about 0.10, 0.20, 0.30, 0.40, 0.50, 0.60, 0.70, 0.80, 0.90, 1.0, 1.10, 1.20, 1.30, 1.40, 1.50, 1.60, 1.70, 1.80, 1.90, 2.0, 2.10, 2.20, 2.30, 2.40, 2.50, 2.60, 2.70, 2.80, 2.90, 3.0, 3.10, 3.20, 3.30, 3.40, 3.50, 3.60, 3.70, 3.80, 3.90, 4.0, 5.0, 10.0, 15.0, 20.0, 25.0, 30.0, 35.0, 40.0, 45.0, 50.0, 55.0, 60.0, 65.0, 70.0, 75.0, 80.0, 85.0, 90.0, 95.0, 100.0, 115.0, 120.0, 125.0, 130.0, 135.0, 140.0, 145.0, 150.0 fold increase over endogenous amount of the active agent in an otherwise identical cell or a nucleated parent cell.
- the WSGR Docket No.53712-720.601 amount of the active agent and the amount of the comparable endogenous active agent is determined by flow cytometry (FACS).
- the active agent may be a cytokine.
- the cytokine may be expressed by the mRNA in the enucleated cell.
- the cytokine may be expressed by the enucleated cell on the surface of the enucleated cell.
- the cytokine polypeptide encoded by the exogenous mRNA has decreased toxicity in the subject as compared to direct delivery of the cytokine polypeptide.
- the cytokine may comprise a transmembrane domain.
- the mRNA may encode the cytokine and the transmembrane domain.
- the cytokine may be attached to the cell surface of the enucleated cells.
- the cytokine may be attached, complexed, tethered, connected, coupled, linked, or any of the like to the cell surface of the enucleated cell.
- the cytokine may be attached to the cell surface of an enucleated cell exogenously.
- the cytokine is not delivered to a target tissue or microenvironment by an enucleated cell.
- the cytokine is not secreted to a target tissue or microenvironment by an enucleated cell.
- the mRNA encodes a cytokine or an antigen-binding fragment of a cytokine.
- the cytokine is an antigen-binding fragment of said cytokine.
- the cytokine is a full-length cytokine.
- the enucleated cell expresses an abundance of a cytokine polypeptide that is at least 0.1 fold to at least 5.0 fold higher than an enucleated cell expressing an abundance of a comparable naturally-occurring cytokine polypeptide.
- the enucleated cell expresses an abundance of a cytokine polypeptide that is at least 0.1 fold than an enucleated cell expressing an abundance of a comparable naturally-occurring cytokine polypeptide. In some embodiments, the enucleated cell expresses an abundance of a cytokine polypeptide that is at least 0.2 fold than an enucleated cell expressing an abundance of a comparable naturally-occurring cytokine polypeptide. In some embodiments, the enucleated cell expresses an abundance of a cytokine polypeptide that is at least 0.3 fold than an enucleated cell expressing an abundance of a comparable naturally-occurring cytokine polypeptide.
- the enucleated cell expresses an abundance of a cytokine polypeptide that is at least 0.4 fold than an enucleated cell expressing an abundance of a comparable naturally- occurring cytokine polypeptide. In some embodiments, the enucleated cell expresses an abundance of a cytokine polypeptide that is at least 0.5 fold than an enucleated cell expressing an abundance of a comparable naturally-occurring cytokine polypeptide. In some embodiments, the enucleated cell expresses an abundance of a cytokine polypeptide that is at least 0.6 fold than an enucleated cell expressing an abundance of a comparable naturally-occurring cytokine polypeptide.
- the enucleated cell expresses an abundance of a cytokine polypeptide that is at least 0.7 fold than an enucleated cell expressing an abundance of a WSGR Docket No.53712-720.601 comparable naturally-occurring cytokine polypeptide. In some embodiments, the enucleated cell expresses an abundance of a cytokine polypeptide that is at least 0.8 fold than an enucleated cell expressing an abundance of a comparable naturally-occurring cytokine polypeptide.
- the enucleated cell expresses an abundance of a cytokine polypeptide that is at least 0.9 fold than an enucleated cell expressing an abundance of a comparable naturally- occurring cytokine polypeptide. In some embodiments, the enucleated cell expresses an abundance of a cytokine polypeptide that is at least 1.0 fold than an enucleated cell expressing an abundance of a comparable naturally-occurring cytokine polypeptide. In some embodiments, the enucleated cell expresses an abundance of a cytokine polypeptide that is at least 1.2 fold than an enucleated cell expressing an abundance of a comparable naturally-occurring cytokine polypeptide.
- the enucleated cell expresses an abundance of a cytokine polypeptide that is at least 1.4 fold than an enucleated cell expressing an abundance of a comparable naturally-occurring cytokine polypeptide. In some embodiments, the enucleated cell expresses an abundance of a cytokine polypeptide that is at least 1.6 fold than an enucleated cell expressing an abundance of a comparable naturally-occurring cytokine polypeptide. In some embodiments, the enucleated cell expresses an abundance of a cytokine polypeptide that is at least 1.8 fold than an enucleated cell expressing an abundance of a comparable naturally- occurring cytokine polypeptide.
- the enucleated cell expresses an abundance of a cytokine polypeptide that is at least 2.0 fold than an enucleated cell expressing an abundance of a comparable naturally-occurring cytokine polypeptide. In some embodiments, the enucleated cell expresses an abundance of a cytokine polypeptide that is at least 2.2 fold than an enucleated cell expressing an abundance of a comparable naturally-occurring cytokine polypeptide. In some embodiments, the enucleated cell expresses an abundance of a cytokine polypeptide that is at least 2.4 fold than an enucleated cell expressing an abundance of a comparable naturally-occurring cytokine polypeptide.
- the enucleated cell expresses an abundance of a cytokine polypeptide that is at least 2.6 fold than an enucleated cell expressing an abundance of a comparable naturally-occurring cytokine polypeptide. In some embodiments, the enucleated cell expresses an abundance of a cytokine polypeptide that is at least 2.8 fold than an enucleated cell expressing an abundance of a comparable naturally- occurring cytokine polypeptide. In some embodiments, the enucleated cell expresses an abundance of a cytokine polypeptide that is at least 3.0 fold than an enucleated cell expressing an abundance of a comparable naturally-occurring cytokine polypeptide.
- the enucleated cell expresses an abundance of a cytokine polypeptide that is at least 3.2 fold than an enucleated cell expressing an abundance of a comparable naturally-occurring cytokine polypeptide. In some embodiments, the enucleated cell expresses an abundance of a cytokine WSGR Docket No.53712-720.601 polypeptide that is at least 3.4 fold than an enucleated cell expressing an abundance of a comparable naturally-occurring cytokine polypeptide.
- the enucleated cell expresses an abundance of a cytokine polypeptide that is at least 3.6 fold than an enucleated cell expressing an abundance of a comparable naturally-occurring cytokine polypeptide. In some embodiments, the enucleated cell expresses an abundance of a cytokine polypeptide that is at least 3.8 fold than an enucleated cell expressing an abundance of a comparable naturally- occurring cytokine polypeptide. In some embodiments, the enucleated cell expresses an abundance of a cytokine polypeptide that is at least 4.0 fold than an enucleated cell expressing an abundance of a comparable naturally-occurring cytokine polypeptide.
- the enucleated cell expresses an abundance of a cytokine polypeptide that is at least 4.8 fold than an enucleated cell expressing an abundance of a comparable naturally- occurring cytokine polypeptide. In some embodiments, the enucleated cell expresses an abundance of a cytokine polypeptide that is at least 5.0 fold than an enucleated cell expressing an abundance of a comparable naturally-occurring cytokine polypeptide. In some embodiments, the abundance of the cytokine polypeptide and the abundance of the comparable naturally- occurring cytokine polypeptide is determined by flow cytometry (FACS).
- FACS flow cytometry
- the cytokine polypeptide is coupled to the enucleated cell surface for a certain length of time. In some embodiments, the length of time is following delivery to a subject (e.g., administration) disclosed herein. In some embodiments, a cytokine polypeptide is attached to the cell surface of the enucleated cell for at least 12 hours. In some embodiments, a cytokine polypeptide is attached to the cell surface of the enucleated cell for at least 24 hours. In some embodiments, a cytokine polypeptide is attached to the cell surface of the enucleated cell for at least 36 hours.
- a cytokine polypeptide is attached to the cell surface of the enucleated cell for at least 48 hours. In some embodiments, a cytokine polypeptide is attached to the cell surface of the enucleated cell for at least 72 hours. In some embodiments, a cytokine polypeptide is covalently linked or connected to the cell surface of the enucleated cell for at least 12 hours. In some embodiments, a cytokine polypeptide is covalently linked or connected to the cell surface of the enucleated cell for at least 24 hours.
- a cytokine polypeptide is expressed on a cell surface of an enucleated cell for at least 24 hours. In some embodiments, a cytokine polypeptide can be expressed on a cell surface of an enucleated cell for at least 36 hours. In some embodiments, a cytokine polypeptide is expressed on a cell surface of an enucleated cell for at least 48 hours. In some embodiments, a cytokine polypeptide can be expressed on a cell surface of an enucleated cell for at least 72 hours. [0082]
- the enucleated cell disclosed herein may comprise an mRNA encoding a polypeptide.
- the polypeptide may be a cytokine.
- the cytokine may comprise an interleukin.
- the interleukin may comprise IL-12.
- the IL-12 may comprise IL-12 ⁇ .
- IL-12 ⁇ comprises SEQ ID NO: 35.
- IL-12 ⁇ comprises an amino acid sequence having greater than or equal to about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 35.
- the IL-12 may comprise IL-12 ⁇ .
- IL-12 ⁇ comprises SEQ ID NO: 36.
- IL-12 ⁇ comprises an amino acid sequence having greater than or equal to about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 36.
- the IL-12 may comprise IL-12 ⁇ and IL-12 ⁇ .
- the IL-12 ⁇ and IL-12 ⁇ interact with a disulfide bond connecting the IL-12 ⁇ and IL-12 ⁇ .
- the IL-12 may comprise a transmembrane domain, such as a transmembrane from a B7 cell surface ligand.
- the transmembrane from the B7 cell surface ligand is from a B7-2 cell surface ligand.
- B7-2 cell surface ligand comprises SEQ ID NO: 37. In some embodiments, B7-2 cell surface ligand comprises an amino acid sequence having greater than or equal to about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 37.
- the IL-12 comprises IL-12 ⁇ , IL-12 ⁇ , and a transmembrane B7-2 domain. In some embodiments, IL-12 ⁇ , IL-12 ⁇ , and the transmembrane B7-2 domain comprises SEQ ID NO: 33.
- IL-12 ⁇ , IL-12 ⁇ , and the transmembrane B7-2 domain comprises an amino acid sequence having greater than or equal to about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 33.
- the transmembrane domain e.g., transmembrane B7-2, can allow the IL-12 to be tethered to the cell surface.
- the interleukin may be IL-15.
- IL-15 comprises SEQ ID NO: 38.
- IL-15 comprises an amino acid WSGR Docket No.53712-720.601 sequence having greater than or equal to about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 38.
- the IL-15 may further comprise IL-15 receptor alpha (RA).
- IL-15 RA comprises SEQ ID NO: 40.
- IL-15 RA comprises an amino acid sequence having greater than or equal to about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 40.
- the IL-15 RA may comprise a sushi domain.
- the sushi domain comprises SEQ ID NO: 41.
- sushi domain comprises an amino acid sequence having greater than or equal to about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 41.
- the sushi domain can allow the IL-15RA to interact with the IL-15.
- the sushi domain can allow the IL-15RA to bind to the IL-15.
- the IL-15 RA may comprise a transmembrane domain In some embodiments, the transmembrane domain comprises SEQ ID NO: 42.
- transmembrane domain comprises an amino acid sequence having greater than or equal to about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 42.
- the IL-15 RA may comprise a sushi domain and a transmembrane domain.
- the sushi domain comprises cysteine residues that form disulfide bonds, such as cysteine residues at position 3, 29, 45, and 63 of SEQ ID NO: 41.
- the IL-15 and IL-15 RA may be connected.
- the IL-15 and IL-15 RA may be connected by a linker.
- the linker comprises SEQ ID NO: 39.
- linker comprises an amino acid sequence having greater than or equal to about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 39.
- the polypeptide may comprise the IL-15, the IL-15 RA, and the linker.
- the IL-15, the IL-15 RA, and the linker comprises SEQ ID NO: 34.
- the IL- 15, the IL-15 RA, and the linker comprises an amino acid sequence having greater than or equal to about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 34.
- the sequences for these regions may be found in Table 9.
- Table 9 Amino acid sequences for IL-12 and IL-15 complexes WSGR Docket No.53712-720.601 [0083]
- the enucleated cell disclosed herein may comprise more than one mRNAs encoding more than one polypeptides.
- the polypeptides may comprise cytokines.
- the cytokines may comprise interleukins.
- the interleukins may comprise IL-12 and IL-15.
- IL-12 and IL-15 are expressed on the surface of the enucleated cell.
- the polypeptides comprise a cytokine and an immune checkpoint inhibitor.
- the enucleated cell disclosed herein may comprise an immune checkpoint inhibitor.
- the immune checkpoint inhibitor may comprise a PD-1 inhibitor, a PD-L1 inhibitor, a TIM-3 inhibitor, a LAG-3 inhibitor, a TIGIT inhibitor, a CD47 inhibitor, a B7 inhibitor, a CD 137 inhibitor, a CTLA-4 inhibitor, or any combination thereof.
- the immune checkpoint inhibitor may be encoded by a second exogenous mRNA in the enucleated cell.
- the cells of the present disclosure comprise at least one therapeutic agent.
- the cells are enucleated, such as with the methods of enucleation disclosed herein.
- the therapeutic agent is or comprises an active agent of the present disclosure.
- an active agent comprises at least one of a DNA molecule, a RNA molecule, a protein (e.g., an enzyme, an antibody, an antigen, a toxin, cytokine, a protein hormone, a growth factor, a cell surface receptor, or a vaccine), a peptide (e.g., a peptide hormone or an antigen), a small molecule (e.g., a steroid, a polyketide, an alkaloid, a toxin, an antibiotic, an antiviral, a colchicine, a taxol, a mitomycin, or emtansine), a gene editing factor, a nanoparticle, or another active agent (e.g., bacteria, bacterial spores, bacteriophages, bacterial components, viruses (e.g., oncolytic viruses), exosomes, lipids, or ions).
- a protein e.g., an enzyme, an antibody, an antigen, a toxin
- the amount of the therapeutic agent is about 3.00 to about 140.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 3.00 to about 145.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 3.00 to about 150.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 4.00 to about 5.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 4.00 to about 10.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 4.00 to about 15.00 fold increase over endogenous amount of the therapeutic agent.
- the amount of the therapeutic agent is about 4.00 to about 50.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 4.00 to about 55.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 4.00 to about 60.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 4.00 to about 65.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 4.00 to about 70.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 4.00 to about 75.00 fold increase over endogenous amount of the therapeutic agent.
- the amount of the therapeutic agent is about 5.00 to about 20.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 5.00 to about 25.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 5.00 to about 30.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 5.00 to about 35.00 fold increase over endogenous amount of the therapeutic agent. In some WSGR Docket No.53712-720.601 embodiments, the amount of the therapeutic agent is about 5.00 to about 40.00 fold increase over endogenous amount of the therapeutic agent.
- the amount of the therapeutic agent is about 35.00 to about 115.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 35.00 to about 120.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 35.00 to about 125.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 35.00 to about 130.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 35.00 to about 135.00 fold increase over endogenous amount of the therapeutic agent.
- the amount of the therapeutic agent is about 45.00 to about 100.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 45.00 to about 105.00 fold increase over endogenous amount of the therapeutic agent. In some WSGR Docket No.53712-720.601 embodiments, the amount of the therapeutic agent is about 45.00 to about 110.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 45.00 to about 115.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 45.00 to about 120.00 fold increase over endogenous amount of the therapeutic agent.
- the amount of the therapeutic agent is about 55.00 to about 70.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 55.00 to about 75.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 55.00 to about 80.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 55.00 to about 85.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 55.00 to about 90.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 55.00 to about 95.00 fold increase over endogenous amount of the therapeutic agent.
- the amount of the therapeutic agent is about 60.00 to about 65.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 60.00 to about 70.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 60.00 to about 75.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 60.00 to about 80.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 60.00 to about 85.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 60.00 to about 90.00 fold increase over endogenous amount of the therapeutic agent.
- the amount of the therapeutic agent is about 60.00 to about 95.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 60.00 to about 100.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 60.00 to about 105.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 60.00 to about 110.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 60.00 to about 115.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 60.00 to about 120.00 fold increase over endogenous amount of the therapeutic agent.
- the amount of the therapeutic agent is about 65.00 to about 95.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 65.00 to about 100.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 65.00 to about 105.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 65.00 to about 110.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 65.00 to about 115.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 65.00 to about 120.00 fold increase over endogenous amount of the therapeutic agent.
- the amount of the therapeutic agent is about 65.00 to about 125.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 65.00 to about 130.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 65.00 to about 135.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 65.00 to about 140.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 65.00 to about 145.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 65.00 to about 150.00 fold increase over endogenous amount of the therapeutic agent.
- the amount of the therapeutic agent is about 70.00 to about 75.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 70.00 to about 80.00 fold increase over endogenous amount of the therapeutic agent. In some WSGR Docket No.53712-720.601 embodiments, the amount of the therapeutic agent is about 70.00 to about 85.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 70.00 to about 90.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 70.00 to about 95.00 fold increase over endogenous amount of the therapeutic agent.
- the amount of the therapeutic agent is about 70.00 to about 100.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 70.00 to about 105.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 70.00 to about 110.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 70.00 to about 115.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 70.00 to about 120.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 70.00 to about 125.00 fold increase over endogenous amount of the therapeutic agent.
- the amount of the therapeutic agent is about 70.00 to about 130.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 70.00 to about 135.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 70.00 to about 140.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 70.00 to about 145.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 70.00 to about 150.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 75.00 to about 80.00 fold increase over endogenous amount of the therapeutic agent.
- the amount of the therapeutic agent is about 75.00 to about 85.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 75.00 to about 90.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 75.00 to about 95.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 75.00 to about 100.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 75.00 to about 105.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 75.00 to about 110.00 fold increase over endogenous amount of the therapeutic agent.
- the amount of the therapeutic agent is about 75.00 to about 115.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 75.00 to about 120.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 75.00 to about 125.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 75.00 to about 130.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 75.00 to about 135.00 fold increase over endogenous amount of the therapeutic agent.
- the amount of the therapeutic agent is about 75.00 to about 140.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 75.00 to about 145.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 75.00 to about 150.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 80.00 to about 85.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 80.00 to about 90.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 80.00 to about 95.00 fold increase over endogenous amount of the therapeutic agent.
- the amount of the therapeutic agent is about 85.00 to about 100.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 85.00 to about 105.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 85.00 to about 110.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 85.00 to about 115.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 85.00 to about 120.00 fold increase over endogenous amount of the therapeutic agent.
- the amount of the therapeutic agent is about 85.00 to about 125.00. In some embodiments, the amount of the therapeutic agent is about 85.00 to about 130.00.In some embodiments, the amount of the therapeutic agent is about 85.00 to about 135.00.In some embodiments, the amount of the therapeutic agent is about 85.00 to about 140.00.In some embodiments, the amount of the therapeutic agent is about 85.00 to about 145.00.In some embodiments, the amount of the therapeutic agent is about 85.00 to about 150.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 90.00 to about 95.00 fold increase over endogenous amount of the therapeutic agent.
- the amount of the therapeutic agent is about 90.00 to about 100.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 90.00 to about 105.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 90.00 to about 110.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 90.00 to about 115.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 90.00 to about 120.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 90.00 to about 125.00 fold increase over endogenous amount of the therapeutic agent.
- the amount of the therapeutic agent is about 90.00 to about 130.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 90.00 to about 135.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 90.00 to about 140.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 90.00 to about 145.00 fold increase WSGR Docket No.53712-720.601 over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 90.00 to about 150.00 fold increase over endogenous amount of the therapeutic agent.
- the amount of the therapeutic agent is about 95.00 to about 100.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 95.00 to about 105.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 95.00 to about 110.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 95.00 to about 115.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 95.00 to about 120.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 95.00 to about 125.00 fold increase over endogenous amount of the therapeutic agent.
- the amount of the therapeutic agent is about 95.00 to about 130.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 95.00 to about 135.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 95.00 to about 140.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 95.00 to about 145.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 95.00 to about 150.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 100.00 to about 105.00 fold increase over endogenous amount of the therapeutic agent.
- the amount of the therapeutic agent is about 100.00 to about 140.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 100.00 to about 145.00 fold increase WSGR Docket No.53712-720.601 over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 100.00 to about 150.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 105.00 to about 110.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 105.00 to about 115.00 fold increase over endogenous amount of the therapeutic agent.
- the amount of the therapeutic agent is about 105.00 to about 120.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 105.00 to about 125.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 105.00 to about 130.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 105.00 to about 135.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 105.00 to about 140.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 105.00 to about 145.00 fold increase over endogenous amount of the therapeutic agent.
- the amount of the therapeutic agent is about 105.00 to about 150.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 110.00 to about 115.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 110.00 to about 120.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 110.00 to about 125.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 110.00 to about 130.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 110.00 to about 135.00 fold increase over endogenous amount of the therapeutic agent.
- the amount of the therapeutic agent is about 110.00 to about 140.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 110.00 to about 145.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 110.00 to about 150.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 115.00 to about 120.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 115.00 to about 125.00 fold increase over endogenous amount of the therapeutic agent.
- the amount of the therapeutic agent is about 115.00 to about 130.00 fold increase WSGR Docket No.53712-720.601 over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 115.00 to about 135.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 115.00 to about 140.00 fold increase over endogenous amount of the therapeutic agent. n some embodiments, the amount of the therapeutic agent is about 115.00 to about 145.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 115.00 to about 150.00 fold increase over endogenous amount of the therapeutic agent.
- the amount of the therapeutic agent is about 120.00 to about 125.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 120.00 to about 130.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 120.00 to about 135.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 120.00 to about 140.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 120.00 to about 145.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 120.00 to about 150.00 fold increase over endogenous amount of the therapeutic agent.
- the amount of the therapeutic agent is about 125.00 to about 130.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 125.00 to about 135.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 125.00 to about 140.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 125.00 to about 145.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 125.00 to about 150.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 130.00 to about 135.00 fold increase over endogenous amount of the therapeutic agent.
- the amount of the therapeutic agent is about 130.00 to about 140.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 130.00 to about 145.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 130.00 to about 150.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 135.00 to about 140.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 135.00 to about 145.00 fold increase WSGR Docket No.53712-720.601 over endogenous amount of the therapeutic agent.
- the amount of the therapeutic agent is about 135.00 to about 150.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 140.00 to about 145.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 140.00 to about 150.00 fold increase over endogenous amount of the therapeutic agent. In some embodiments, the amount of the therapeutic agent is about 145.00 to about 150.00 fold increase over endogenous amount of the therapeutic agent.
- the amount of the therapeutic agent is about 0.10, 0.20, 0.30, 0.40, 0.50, 0.60, 0.70, 0.80, 0.90, 1.0, 1.10, 1.20, 1.30, 1.40, 1.50, 1.60, 1.70, 1.80, 1.90, 2.0, 2.10, 2.20, 2.30, 2.40, 2.50, 2.60, 2.70, 2.80, 2.90, 3.0, 3.10, 3.20, 3.30, 3.40, 3.50, 3.60, 3.70, 3.80, 3.90, 4.0, 5.0, 10.0, 15.0, 20.0, 25.0, 30.0, 35.0, 40.0, 45.0, 50.0, 55.0, 60.0, 65.0, 70.0, 75.0, 80.0, 85.0, 90.0, 95.0, 100.0, 115.0, 120.0, 125.0, 130.0, 135.0, 140.0, 145.0, 150.0 fold increase over endogenous amount of the therapeutic agent in an otherwise identical cell or a nucleated parent cell.
- the amount of the therapeutic agent is greater than or equal to about 0.10, 0.20, 0.30, 0.40, 0.50, 0.60, 0.70, 0.80, 0.90, 1.0, 1.10, 1.20, 1.30, 1.40, 1.50, 1.60, 1.70, 1.80, 1.90, 2.0, 2.10, 2.20, 2.30, 2.40, 2.50, 2.60, 2.70, 2.80, 2.90, 3.0, 3.10, 3.20, 3.30, 3.40, 3.50, 3.60, 3.70, 3.80, 3.90, 4.0, 5.0, 10.0, 15.0, 20.0, 25.0, 30.0, 35.0, 40.0, 45.0, 50.0, 55.0, 60.0, 65.0, 70.0, 75.0, 80.0, 85.0, 90.0, 95.0, 100.0, 115.0, 120.0, 125.0, 130.0, 135.0, 140.0, 145.0, 150.0 fold increase over endogenous amount of the therapeutic agent in an otherwise identical cell or nucleated parent cell.
- the amount of the therapeutic agent is less than or equal to about 0.10, 0.20, 0.30, 0.40, 0.50, 0.60, 0.70, 0.80, 0.90, 1.0, 1.10, 1.20, 1.30, 1.40, 1.50, 1.60, 1.70, 1.80, 1.90, 2.0, 2.10, 2.20, 2.30, 2.40, 2.50, 2.60, 2.70, 2.80, 2.90, 3.0, 3.10, 3.20, 3.30, 3.40, 3.50, 3.60, 3.70, 3.80, 3.90, 4.0, 5.0, 10.0, 15.0, 20.0, 25.0, 30.0, 35.0, 40.0, 45.0, 50.0, 55.0, 60.0, 65.0, 70.0, 75.0, 80.0, 85.0, 90.0, 95.0, 100.0, 115.0, 120.0, 125.0, 130.0, 135.0, 140.0, 145.0, 150.0 fold increase over endogenous amount of the therapeutic agent in an otherwise identical cell or nucleated parent cell. In some embodiments, the amount of the therapeutic agent and the amount of the
- the therapeutic agent is recombinantly expressed by the enucleated cell or parent cell thereof.
- the parent cell from which the enucleated cell is derived or obtained is engineered to produce or express the therapeutic agent.
- expression of the therapeutic agent is stable (e.g., permanent).
- the expression of the therapeutic agent by the parent cell is transient (e.g., non- permanent).
- the parent cell is enucleated prior to engineering the WSGR Docket No.53712-720.601 enucleated cell to recombinantly express the therapeutic agent.
- the parent cell is engineered to recombinantly express the therapeutic agent prior to enucleation.
- the therapeutic agent is not naturally expressed (e.g., in the absence of engineering) in the cell from which the enucleated cell was derived or obtained (e.g., the therapeutic agent is exogenous to the parent cell). In some embodiments, the therapeutic agent is not naturally expressed in the subject (e.g., the therapeutic agent is exogenous to the subject).
- the therapeutic agent is not naturally expressed in the subject at the intended site of therapy (e.g., a tumor, or a particular tissue such as the brain, the intestine, the lungs, the heart, the liver, the spleen, the pancreas, muscles, eyes, and the like) (e.g., the therapeutic agent is exogenous to the intended site of therapy).
- the level of the therapeutic agent is not naturally occurring in the enucleated cell of the parent cell, such as over expression or under expression of the therapeutic agent.
- the therapeutic agent is derived from a synthetic cell and loaded into the enucleated cell.
- the therapeutic agent may be endocytosed into the cell prior to or after enucleation of the cell.
- the therapeutic agent may be synthesized by the cell.
- the enucleated cell comprises a plurality of therapeutic agents.
- the enucleated cell comprises at least 1 (e.g., at least 1, 2, 3, 4, 5, or more) different DNA molecules, RNA molecules, proteins, peptides, small molecule active agents, or gene-editing factors, in any combination.
- a therapeutic agent comprises a DNA molecule and a small molecule active agent.
- the therapeutic agent comprises two different small molecule active agents.
- the therapeutic agent comprises a chemokine receptor (e.g., for targeting) and a small molecule active agent.
- the therapeutic agent comprises a polypeptide.
- the polypeptide is exogenous.
- the polypeptide is encoded by an exogenous polynucleotide delivered into the parent cell or the enucleated cell.
- the polypeptide is synthesized by at least one intracellular organelle of the enucleated cell.
- the polypeptide is tethered to the enucleated cell.
- the polypeptide is expressed on the cell surface or the enucleated cell.
- the enucleated cell expresses the polypeptide in a target environment.
- the target environment is a microenvironment.
- the microenvironment is a tumor microenvironment.
- the enucleated cell expresses the polypeptide at a target cell.
- the target cell is a cancer cell.
- the cancer cell expresses the cancer biomarker of any cancer described WSGR Docket No.53712-720.601 herein.
- the target cell is an endothelial cell.
- the endothelial cell expresses an endothelial biomarker described herein.
- the endothelial cell is a blood vessel cell. In some embodiments, the endothelial cell is a lymphatic vessel cell.
- the exogenous polypeptide comprises a cytokine.
- An “exogenous” polypeptide provided herein may refer to a presence of the polypeptide that is exogenous to the cell or enucleated cell, or an amount or level of expression of the polypeptide that exogenous to the cell or enucleated cell.
- the cytokine comprises a membrane binding domain. In some embodiments, the exogenous polypeptide comprises a soluble cytokine.
- the cytokine comprises interferons. In some embodiments, the cytokine comprises a lymphokine. In some embodiments, the cytokine comprises a tumor necrosis factor. In some embodiments, the cytokine comprises a monokine. In some embodiments, the cytokine comprises a colony-stimulating factor. In some embodiments, the cytokine comprises a transforming growth factor.
- Non-limiting examples of cytokines include bFGF, TNF- ⁇ , IL-10, IL-12(p70), IL-1 ⁇ , IL-2, IL-6, GM-CSF, IL-13, IFN- ⁇ , TGF- ⁇ 1, TGF-02, TGF- ⁇ 3, and IL-15.
- the exogenous polypeptide comprises an interleukin. In some embodiments, the exogenous polypeptide comprises more than one interleukin.
- interleukins include IL1, IL2, IL3, IL4, IL5, IL6, IL7, IL8 (CXCL8), IL9, IL10, IL11, IL12, IL13, IL14, IL15, IL16, IL17, IL18, IL19, IL20, IL21, IL22, IL23, IL24, IL25, IL26, IL27, IL28, IL29, IL30, IL31, IL32, IL33, IL35, or IL36.
- a cytokine of the composition is an interleukin or a mutant thereof, including, but not limited to, wild-type and mutant forms of IL1, IL2, IL3, IL4, IL5, IL6, IL7, IL8. (CXCL8), IL9, IL10, IL11, IL12, IL13, IL14, IL15, IL16, IL17, IL18, IL19, IL20, IL21, IL22, IL23, IL24, IL25, IL26, IL27, IL28, Il29, IL30, IL31, IL32, IL33, IL35, or IL36.
- the cytokine comprises IL-12.
- the IL-12 comprises an IL-12 complex.
- the IL-12 complex comprises SEQ ID NO: 33.
- the IL-12 complex comprises an amino acid sequence having greater than or equal to about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 33.
- the IL*12 complex comprises IL-12 ⁇ , IL-12 ⁇ , and a transmembrane domain.
- the exogenous polypeptide comprises a peptide sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 99%, or more identical to SEQ ID NO: 33. In some embodiments, the exogenous polypeptide comprises IL-12 ⁇ or a catalytically active fragment thereof. In some embodiments, the exogenous polypeptide comprises a peptide sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 99%, or more identical to SEQ ID NO: 35. In some embodiments, the exogenous polypeptide comprises IL-12 ⁇ or a catalytically active fragment thereof.
- the IL-15 complex comprises an amino acid sequence having greater than or equal to about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 34.
- the IL-15 complex is formed by the noncovalent assembly of IL-15 with dimeric or monomeric sushi domain of IL-15 receptor ⁇ (SuIL-15 RA).
- the complex is a fusion protein, e.g., with IgG4 Fc.
- the IL-15 complex comprises IL-15 RA with a sushi domain and a transmembrane domain connected to IL-15 by a linker.
- the cytokine comprises IL-15 and IL-12 in the same enucleated cell.
- the exogenous polypeptide comprises a peptide sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 99%, or more identical to SEQ ID NO: 34.
- the exogenous polypeptide comprises IL-15 or a catalytically active fragment thereof.
- the exogenous polypeptide comprises a peptide sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 99%, or more identical to SEQ ID NO: 38.
- the exogenous polypeptide comprises a linker.
- the exogenous polypeptide comprises a peptide sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 99%, or more identical to SEQ ID NO: 39.
- the exogenous WSGR Docket No.53712-720.601 polypeptide comprises IL-15 RA or a catalytically active fragment thereof.
- the exogenous polypeptide comprises a peptide sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 99%, or more identical to SEQ ID NO: 40.
- the exogenous polypeptide comprises a sushi domain of IL-15 RA or a catalytically active fragment thereof.
- the exogenous polypeptide comprises a peptide sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 99%, or more identical to SEQ ID NO: 41. In some embodiments, the exogenous polypeptide comprises a transmembrane domain of IL-15 RA or a catalytically active fragment thereof. In some embodiments, the exogenous polypeptide comprises a peptide sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 99%, or more identical to SEQ ID NO: 42. In some embodiments, the exogenous polypeptide comprises a tumor necrosis factor (TNF) superfamily member polypeptide or a catalytically active fragment thereof.
- TNF tumor necrosis factor
- TNF superfamily member polypeptide examples include Lymphotoxin alpha (TNF ⁇ ), Tumor necrosis factor (TNF ⁇ ), Lymphotoxin beta (TNF ⁇ ), OX40 ligand (CD252, Gp34, or CD134L), CD40 ligand (CD154, TRAP, Gp39, or T-BAM), Fas ligand (CD178, APTL, or CD95L), CD27 ligand (CD70), CD30 ligand (CD153), CD137 ligand (4-1 BBL), TNF-related apoptosis-inducing ligand (CD253 or APO-2L), Receptor activator of nuclear factor kappa- ⁇ ligand (CD254, OPGL, TRANCE, or ODF), TNF-related weak inducer of apoptosis (APO-3L or DR3L), a proliferation-inducing ligand (CD256, TALL-2, or TRDL1), B-cell activating factor (CD257,
- the therapeutic agent comprises any one of the immune checkpoint molecule described herein or an immune checkpoint molecule inhibitor for inhibiting any one of the immune checkpoint molecule described herein.
- the immune checkpoint molecule include PD-1, PD-L1, CTLA-4, VISTA, PDCD1LG2 (CD273), B7-H3 (also called CD276), A2AR, CD27, LAG3, TIM-3, T cell immunoreceptor with Ig and ITIM domains (TIGIT), CD73, NKG2A, PVRIG, PVRL2, CEACAM1, CEACAM5, CEACAM6, FAK, CCR-2, CCL-2, LIF, CD47, SIRP ⁇ , M-CSF, CSF-1R, IL-3, IL-1RAP, IL-8, SEMA4D, Angiopoietin-2, CLEVER-1, Axl, phosphatidylserine or a fragment thereof.
- the enucleated cell comprising the targeting moiety localizes at the target cell or target environment in a subject with at least a 5% increased as compared to localization of a comparable enucleated cell lacking the targeting moiety. In some embodiments, the enucleated cell comprising the targeting moiety localizes at the target cell or target environment in a subject with at least a 10% increased as compared to localization of a comparable enucleated cell lacking the targeting moiety. In some embodiments, the enucleated cell comprising the targeting moiety localizes at the target cell or target environment in a subject with at least a 20% increased as compared to localization of a comparable enucleated cell lacking the targeting moiety.
- the enucleated cell comprising the targeting moiety localizes at the target cell or target environment in a subject with at least a 90% increased as compared to localization of a comparable enucleated cell lacking the targeting moiety. In some embodiments, the enucleated cell comprising the targeting moiety localizes at the target cell or target environment in a subject with at least a 100% increased as compared to localization of a comparable enucleated cell lacking the targeting moiety. [0101] In some embodiments, the targeting moiety comprises an exogenous antibody or an exogenous antigen-binding fragment for targeting a biomarker described herein.
- the cells are enucleated, such as with the methods of enucleation disclosed herein.
- transmembrane moiety is coupled to a polypeptide.
- the polypeptide is a cytokine.
- the polypeptide is an interleukin.
- the polypeptide is a single-domain antibody or antigen-binding fragment thereof, a therapeutic agent disclosed here, or a combination thereof.
- the transmembrane moiety is coupled by way of a covalent bond.
- the transmembrane moiety is a fusion protein comprising the single-domain antibody or antigen-binding fragment thereof, a therapeutic agent disclosed here, or a combination thereof.
- the exogenous polypeptide is complexed to the transmembrane moiety.
- the transmembrane moiety comprises a full length protein or a variation thereof or a fragment thereof.
- the transmembrane moiety is endogenous to the parent cell that is being enucleated for obtaining the enucleated cell.
- the transmembrane moiety may be an exogenous transmembrane moiety to the parent cell or to the enucleated cell.
- the enucleated cell comprises a cytokine.
- the cytokine comprises an interleukin.
- the cytokine comprises an IL-12 (interleukin 12).
- the cytokine comprises an IL-15 (interleukin 15).
- the exogenous cytokine or fragment thereof is complexed with a transmembrane moiety.
- the transmembrane moiety comprises a WSGR Docket No.53712-720.601 transmembrane polypeptide.
- the exogenous cytokine or fragment thereof is complexed with N-terminus of the transmembrane polypeptide.
- IL-12 is coupled to a cell surface protein ligand.
- the cell surface protein ligand is from the B7 family of cell surface ligand proteins.
- B7 family members includes but is not limited to B7.1, B7.2, B7-H4, and B7-H3.
- Il-12 is coupled to a portion of a cell surface protein ligand.
- IL-12 is coupled to only a transmembrane portion of a cell surface protein ligand.
- IL-12 is coupled to the transmembrane portion of a B7 family member.
- IL-12 is coupled to the transmembrane portion of B7.1.
- IL-12 comprises IL-12 ⁇ .
- IL-12 comprises IL-12 ⁇ and IL-12 ⁇ .
- IL-12 ⁇ comprises a signal peptide and an IL-12 subunit alpha chain.
- IL-12 ⁇ comprises an IL-12 subunit alpha chain.
- IL-15 may be coupled to IL-15 R ⁇ to the exoplasmic side of the cell membrane of the enucleated cell. As depicted in FIG.10A, IL-15 R ⁇ spans the cell membrane of an enucleated cell. The portion of IL-15 R ⁇ on the exoplasmic surface is coupled to IL-15 by a linker. On the opposite end of IL-15 from the linker connecting to IL-15 R ⁇ is a signal peptide. In some embodiments, IL-15 R ⁇ comprises a Sushi domain and a transmembrane region.
- the enucleated cells may be engineered with immune evading moieties (e.g., CD34+) to avoid an antigenic response in the host.
- Enucleated cells may also be engineered to express cell-surface receptors (e.g, adhesion molecules, chemokine receptors) used for cellular homing, chemokine sensing, and other biological functions that are essential to targeting damaged tissue.
- An immune-evading moiety may comprise a signaling peptide, or portion thereof, that reduces cellular phagocytosis through its interaction with a signal receptor protein expressed by phagocytic cells such as macrophages and dendritic cells.
- the immune-evading moiety blocks immune cell recognition or immune cell activation.
- the compositions, methods and systems of the present disclosure utilize an enucleated cell platform developed by the inventors of the present disclosure and initial described in United States Patent Application No.10,927,349, which is hereby incorporated by reference in its entirety.
- additional utility and advantages of the enucleated cells disclosed herein are discussed in U.S. Patent Application No.18/176,259, filed February 28, 2023; U.S. Patent Application No.17/885,867, filed August 11, 2022; and U.S. Patent Application No. 18/190,838, filed March 27, 2023, each of which is hereby incorporated by reference in its entirety.
- the IL-12 B7TM coding region is preceded by a human eukaryotic translation elongation factor 1 ⁇ 1 promoter (EF1A) and a signal peptide or Kozak.
- the IL-12 B7TM coding region comprises SEQ ID NO: 10.
- the IL-12 B7TM coding region comprises a nucleotide sequence having greater than or equal to about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 10.
- IL-15 is encoded by a vector.
- IL-15 and IL-15 R ⁇ are encoded by a vector.
- IL-15, IL-15 R ⁇ , and a linker are encoded by a vector.
- IL-15, IL-15 R ⁇ , a linker, and a signal peptide are encoded by a vector.
- the vector is a lentiviral vector.
- the vector is a mammalian expression vector. As depicted in FIG.10B, IL-15 and IL-15 R ⁇ may be inserted in a vector such as the vector depicted (vector ID: VB190220- WSGR Docket No.53712-720.601 1118ayw).
- compositions described herein comprising the enucleated cells or the compositions described herein.
- the pharmaceutical formulations further comprise a pharmaceutically acceptable: carrier, excipient, diluent, or nebulized inhalant.
- the pharmaceutical formulations include two or more active agents, or two or more therapeutic agents as disclosed herein.
- the two or more active agents are contained in a single dosage unit such as, for example, when the enucleated cell comprises two or more therapeutic agents.
- the two or more active agents are contained in separate dosage units such as when the enucleated cell is administered separately from an additional therapeutic agent or adjuvant.
- the active agents that may be, in some embodiments, the additional therapeutic agent include a chemotherapeutic agent, cytotoxic agent, cytokine, growth-inhibitory agent, anti-hormonal agent, anti-angiogenic agent, cardio protectant, and/or checkpoint inhibitor.
- Non-limiting checkpoint inhibitor includes IMP321/Eftilagimod alpha (Immutep), Relatlimab BMS-986016, Ipilimumab (Yervoy), Pembrolizumab (Keytruda), Nivolumab (Opdivo), Cemiplimab (Libtayo), Atezolizumab (Tecentriq), Avelumab (Bavencio), Durvalumab (Imfinzi), Ipilimumab (Yervoy), LAG525, MK-4280, Irinotecan, Oxaliplatin, REGN3767, TSR-033, BI754111, Sym022, FS118 (a bi-specific anti-LAG3/PD-L1 antagonistic mAb), MGD013 (a bi-specific anti-LAG3/PD-1 antagonistic mAb), TSR-022, Niraparib, Bevacizumab, MBG453, Decitabine, Spartalizumab, Sym
- Non-limiting examples of active agents that may be, in some embodiments, the additional therapeutic agent include CPI- WSGR Docket No.53712-720.601 006 (for inhibiting CD73 and allowing T cell and APC activation); Monalizumab (for inhibiting NKG2A); COM701 (for inhibiting PVRIG/PVRL2 and activating T cell); CM24 (for inhibiting CEACAM1 and allowing T and NK cells activation); NEO-201 (for inhibiting CEACAM5 and CEACAM6 which allows T cell activation while interfering with tumor cell growth); Defactinib (for inhibiting FAK and interfering with tumor growth); PF-04136309 (for inhibiting CCR-2 and CCL-2 and allowing T cell recruitment and activation); MSC-1 (for inhibiting LIF and allowing T cell and APC activation while interfering with cancer growth); Hu5F9-G4 (5F9), ALX148,
- composition described herein may include, but not limited to, aqueous liquid dispersions, self-emulsifying dispersions, solid solutions, liposomal dispersions, aerosols, solid dosage forms, powders, immediate release formulations, controlled release formulations, fast melt formulations, tablets, capsules, pills, delayed release formulations, extended release formulations, pulsatile release formulations, multiparticulate formulations, and mixed immediate and controlled release formulations.
- the pharmaceutical formulations including a therapeutic agent may be manufactured in a conventional manner such as, by way of example only, by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or compression processes.
- the pharmaceutical formulations may include at least an exogenous therapeutic agent as an active ingredient in free-acid or free-base form, or in a pharmaceutically acceptable salt form.
- the methods and compositions described herein include the use of N-oxides (if appropriate), crystalline forms, amorphous phases, as well as active metabolites of these compounds having the same type of activity.
- therapeutic agents exist in WSGR Docket No.53712-720.601 unsolvated form or in solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like. The solvated forms of the therapeutic agents are also considered to be disclosed herein.
- pharmaceutical formulations provided herein include one or more preservatives to inhibit microbial activity.
- stabilizing agents include, but are not limited to: (a) about 0.5% to about 2% w/v glycerol, (b) about 0.1% to about 1% w/v methionine, (c) about 0.1% to about 2% w/v monothioglycerol, (d) about 1 mM to about 10 mM EDTA, I about 0.01% to about 2% w/v ascorbic acid, (f) 0.003% to about 0.02% w/v polysorbate 80, (g) 0.001% to about 0.05% w/v.
- polysorbate 20 (h) arginine, (i) heparin, (j) dextran sulfate, (k) cyclodextrins, (l) pentosan polysulfate and other heparinoids, (m) divalent cations such as magnesium and zinc; or (n) combinations thereof.
- aqueous oral dispersions liquids, gels, syrups, elixirs, slurries, suspensions, solid oral dosage forms, aerosols, controlled release formulations, fast melt formulations, effervescent formulations, lyophilized formulations, tablets, powders, pills, dragees, capsules, delayed release formulations, extended release formulations, pulsatile release formulations, multiparticulate formulations, and mixed immediate release and controlled release formulations.
- a therapeutic agent as discussed herein e.g., therapeutic agent is formulated into a pharmaceutical composition suitable for intramuscular, subcutaneous, or intravenous injection.
- formulations suitable for intramuscular, subcutaneous, or intravenous injection include physiologically acceptable sterile aqueous or non-aqueous solutions, dispersions, suspensions or emulsions, and sterile powders for rehydration into sterile injectable solutions or dispersions.
- suitable aqueous and non-aqueous carriers, diluents, solvents, or vehicles include water, ethanol, polyols (propyleneglycol, polyethylene- glycol, glycerol, cremophor and the like), suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters such as ethyl oleate.
- Proper fluidity may be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
- formulations suitable for subcutaneous injection also contain additives such as preserving, wetting, WSGR Docket No.53712-720.601 emulsifying, and dispensing agents.
- Prevention of the growth of microorganisms may be ensured by various antibacterial and antifungal agents such as parabens, chlorobutanol, phenol, sorbic acid, and the like.
- it is desirable to include isotonic agents such as sugars, sodium chloride, and the like.
- Prolonged absorption of the injectable pharmaceutical form may be brought about by the use of agents delaying absorption such as aluminum monostearate and gelatin.
- a pharmaceutical formulations described herein is formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hank’s solution, Ringer’s solution, or physiological saline buffer.
- physiologically compatible buffers such as Hank’s solution, Ringer’s solution, or physiological saline buffer.
- penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.
- appropriate formulations include aqueous or nonaqueous solutions, preferably with physiologically compatible buffers or excipients. Such excipients are known.
- Parenteral injections may involve bolus injection or continuous infusion.
- Pharmaceutical formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multi dose containers, with an added preservative.
- the composition described herein may be in a form suitable for parenteral injection as a sterile suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
- the active ingredient is in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.
- a therapeutic agent is formulated for use as an aerosol, a mist or a powder.
- WSGR Docket No.53712-720.601 other ingredients such as pH adjusters, emulsifiers or dispersing agents, preservatives, surfactants, gelling agents, or buffering and other stabilizing and solubilizing agents are optionally present.
- the nasal dosage form should be isotonic with nasal secretions.
- Pharmaceutical preparations for oral use are obtained by mixing one or more solid excipient with one or more of the compositions described herein, optionally grinding the resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores.
- Suitable excipients include, for example, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methylcellulose, microcrystalline cellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose; or others such as: polyvinylpyrrolidone (PVP or povidone) or calcium phosphate. If desired, disintegrating agents are added such as the cross linked croscarmellose sodium, polyvinylpyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.
- fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol
- cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methylcellulose,
- the pharmaceutical formulations of the exogenous therapeutic agents are in the form of a capsules, including push fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer such as glycerol or sorbitol.
- the push fit capsules contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers.
- the active therapeutic agent is dissolved or suspended in suitable liquids such as fatty oils, liquid paraffin, or liquid polyethylene glycols.
- suitable liquids such as fatty oils, liquid paraffin, or liquid polyethylene glycols.
- stabilizers are added.
- a capsule may be prepared, for example, by placing the bulk blend of the formulation of the therapeutic agent inside of a capsule.
- the formulations non-aqueous suspensions and solutions
- the formulations are placed in standard gelatin capsules or non-gelatin capsules such as capsules comprising HPMC.
- the formulation is placed in a sprinkle capsule, wherein the capsule is swallowed whole or the capsule is opened and the contents sprinkled on food prior to eating.
- compositions for oral administration are in dosages suitable for such administration.
- solid oral dosage forms are prepared by mixing a composition with one or more of the following: antioxidants, flavoring agents, and carrier materials such as binders, suspending agents, disintegration agents, filling agents, surfactants, solubilizers, stabilizers, lubricants, wetting agents, and diluents.
- the solid dosage forms disclosed herein are in the form of a tablet, (including a suspension tablet, a fast-melt WSGR Docket No.53712-720.601 tablet, a bite-disintegration tablet, a rapid-disintegration tablet, an effervescent tablet, or a caplet), a pill, a powder, a capsule, solid dispersion, solid solution, bioerodible dosage form, controlled release formulations, pulsatile release dosage forms, multiparticulate dosage forms, beads, pellets, granules.
- the composition is in the form of a powder.
- Compressed tablets are solid dosage forms prepared by compacting the bulk blend of the formulations described above.
- the pharmaceutical formulations described herein are self- emulsifying drug delivery systems (SEDDS).
- SEDDS self- emulsifying drug delivery systems
- Emulsions are dispersions of one immiscible phase in another, usually in the form of droplets.
- emulsions are created by vigorous mechanical dispersion.
- SEDDS as opposed to emulsions or microemulsions, spontaneously form emulsions when added to an excess of water without any external mechanical dispersion or agitation.
- An advantage of SEDDS is that only gentle mixing is required to distribute the WSGR Docket No.53712-720.601 droplets throughout the solution. Additionally, water or the aqueous phase is optionally added just prior to administration, which ensures stability of an unstable or hydrophobic active ingredient.
- a pharmaceutical formulation is optionally formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hank’s solution, Ringer’s solution, or physiological saline buffer.
- physiologically compatible buffers such as Hank’s solution, Ringer’s solution, or physiological saline buffer.
- penetrants appropriate to the barrier to be permeated are used in the formulation.
- appropriate formulations include aqueous or nonaqueous solutions, preferably with physiologically compatible buffers or excipients.
- Parenteral injections optionally involve bolus injection or continuous infusion. Formulations for injection are optionally presented in unit dosage form, e.g., in ampoules or in multi dose containers, with an added preservative.
- compositions include, e.g., one or a combination of methods: (1) dry mixing, (2) direct compression, (3) milling, (4) dry or non-aqueous granulation, (5) wet granulation, or (6) fusion.
- Other methods include, e.g., spray drying, pan coating, melt granulation, granulation, fluidized bed spray drying or coating (e.g., wurster coating), tangential coating, top spraying, tableting, extruding and the like.
- the compositions are provided that include particles of a therapeutic agent and at least one dispersing agent or suspending agent for oral administration to a subject.
- the pharmaceutical formulations optionally include one or more salts in an amount required to bring osmolality of the composition into an acceptable range.
- salts include those having sodium, potassium or ammonium cations and chloride, citrate, ascorbate, borate, phosphate, bicarbonate, sulfate, thiosulfate or bisulfite anions; suitable salts include sodium chloride, potassium chloride, sodium thiosulfate, sodium bisulfite and ammonium sulfate.
- Other the pharmaceutical formulations optionally include one or more preservatives to inhibit microbial activity.
- An aerosol formulation for nasal administration is generally an aqueous solution designed to be administered to the nasal passages in drops or sprays.
- Nasal solutions may be similar to nasal secretions in that they are generally isotonic and slightly buffered to maintain a pH of about 5.5 to about 6.5, although pH values outside of this range may additionally be used.
- Antimicrobial agents or preservatives may also be included in the formulation.
- An aerosol formulation for inhalations and inhalants may be designed so that the agent or combination of agents is carried into the respiratory tree of the subject when administered by the nasal or oral respiratory route. Inhalation solutions may be administered, for example, by a nebulizer.
- Inhalations or insufflations comprising finely powdered or liquid drugs, may be delivered to the respiratory system as a pharmaceutical aerosol of a solution or suspension of the agent or combination of agents in a propellant, e.g., to aid in disbursement.
- Propellants may be liquefied gases, including halocarbons, for example, fluorocarbons such as fluorinated chlorinated hydrocarbons, hydrochlorofluorocarbons, and hydrochlorocarbons, as well as hydrocarbons and hydrocarbon ethers.
- Halocarbon propellants may include fluorocarbon propellants in which all hydrogens are replaced with fluorine, chlorofluorocarbon propellants in which all hydrogens are replaced with chlorine and at least one fluorine, hydrogen-containing fluorocarbon propellants, and hydrogen- containing chlorofluorocarbon propellants.
- Hydrocarbon propellants useful include, for example, propane, isobutane, n-butane, pentane, isopentane and neopentane.
- a blend of hydrocarbons may also be used as a propellant.
- Ether propellants include, for example, dimethyl ether as well as the ethers.
- An aerosol formulation may also comprise more than one propellant.
- the aerosol formulation comprises more than one propellant from the same class such as two or more fluorocarbons; or more than one, more than two, more than three propellants from different classes such as a fluorohydrocarbon and a hydrocarbon.
- the compositions of the present disclosure may also be dispensed with a compressed gas, e.g., an inert gas such as carbon dioxide, nitrous oxide or nitrogen.
- Aerosol formulations may also include other components, for example, ethanol, isopropanol, propylene glycol, as well as surfactants or other components such as oils and detergents. These components may serve to stabilize the formulation and/or lubricate valve components.
- the aerosol formulation may be packaged under pressure and may be formulated as an aerosol using solutions, suspensions, emulsions, powders and semisolid preparations.
- a solution aerosol formulation comprises a solution of an agent such as a transporter, carrier, or ion channel inhibitor in (substantially) pure propellant or as a mixture of propellant and solvent.
- the solvent may be used to dissolve the agent and/or retard the evaporation of the propellant.
- Solvents may include, for example, water, ethanol and glycols. Any combination of suitable solvents may be use, optionally combined with preservatives, antioxidants, and/or other aerosol components.
- An aerosol formulation may be a dispersion or suspension.
- a suspension aerosol formulation comprises a suspension of an agent or combination of agents, e.g., a transporter, carrier, or ion channel inhibitor, and a dispersing agent.
- Dispersing agents may include, for example, sorbitan trioleate, oleyl alcohol, oleic acid, lecithin and corn oil.
- a suspension aerosol formulation may also include lubricants, preservatives, antioxidant, and/or other aerosol components.
- An aerosol formulation may similarly be formulated as an emulsion.
- the methods comprise treating a disease or a condition of a subject by administering the enucleated cells to the subject.
- the method comprises administering to the subject having the disease or the condition an enucleated cell, wherein the enucleated cell comprises an active agent (e.g., exogenous polypeptide or a catalytically active fragment thereof) coupled to a surface of the enucleated cell.
- the active agent is expressed by the enucleated cell in the absence of the nucleus at the surface of the enucleated cell.
- the active agent is or comprises a cytokine polypeptide, or a catalytically active fragment thereof.
- the resulting enucleated cell is engineered to express and, in some cases, secrete the therapeutic agent such as, for example, an antibody or an antigen- binding fragment thereof (e.g., single-domain antibody).
- the enucleated WSGR Docket No.53712-720.601 cell may be administered to a subject in need thereof to treat a disease or a condition in the subject.
- the enucleated cell of the present disclosure may be prepared in advance and cryopreserved for a length of time. This means, the enucleated cell of the present disclosure (e.g., engineered to express the homing receptors, immune activators, etc.) may be rapidly deployed. Such technical aspect is particular important when the enucleated cell is used to treat a disease or a condition stemmed from an outbreak of pathogen exposure or infection.
- removal of the nucleus involves mechanically removing the nucleus.
- the parent cell may be treated with cytochalasin to soften the cortical actin cytoskeleton.
- enucleated cells are then physically extracted from the cell body by high-speed centrifugation in gradients of Ficoll to generate an enucleated cell. Because enucleate cells and intact nucleated cells sediment to different layers in the Ficoll gradient, enucleated cells may be easily isolated and prepared for therapeutic purposes or fusion to other cells (nucleated or enucleated). The enucleation process is clinically scalable to process tens of millions of cells. In some embodiments, enucleated cells may be used as a disease-homing vehicle to deliver clinically relevant cargos/payloads to treat various diseases.
- a biomolecule e.g., the therapeutic agent, transmembrane moiety, immune-evading moiety, and/or targeting moiety described herein.
- Non-limiting examples of methods that may be used to introduce a biomolecule into the parent cell or the enucleated cell include: liposome mediated transfer, an adenovirus, an adeno-associated virus, a herpes virus, a retroviral based vector, a lentiviral vector, electroporation, microinjection, lipofection, transfection, calcium phosphate transfection, dendrimer-based transfection, cationic polymer transfection, cell squeezing, sonoporation, optical transfection, impalection, hydrodynamic delivery, magnetofection, nanoparticle transfection, or combinations thereof.
- a therapeutic agent, a virus, an antibody, or a nanoparticle may be introduced into the enucleated cells.
- the enucleated cell is preserved via cryopreservation, cryohibernation, or lyophilization.
- Cryopreservation comprises freezing the enucleated cell
- cryohibernation comprises storing the enucleated cell at a temperature that is below room WSGR Docket No.53712-720.601 temperature but without freezing the enucleated cell.
- the enucleated cell is lyophilized.
- the lyophilization of the enucleated cell comprises the use of lyoprotectants for retaining cell viability and biologic function.
- Lyoprotectant comprises addition of reagents, salts, or additives that protects cell during the desiccation process.
- Common lyoprotectants include trehalose, DMSO, methylcellulose, sucrose, antioxidants, human or animal serum proteins, and cellular stress proteins. Additionally, methods for increasing the transport of lyoprotectants inside the cells in suspension can be utilized as a way of improving the viability and function of cells after lyophilization.
- Inflammation cytokine measurements [0199] Finally, in a bilateral E0771 TNBC model, tumors were injected unilaterally with 3 doses of intertumoral enucleated cells that secreted IL-12 or PBS (control), and bilateral tumor size measured over time. Unilateral injection of intertumoral enucleated cells that secreted IL-12 reduced tumor growth in both tumors compared to controls, indicating that injection at a single site of enucleated cells that secreted IL-12 induced a systemic antitumor response to limit tumor growth at a distant site (contralateral tumor).
- RNA-seq datasets generated from human TNBC primary tumors TME, and well-established mouse models of TNBC (EO771 and 4T1) were interrogated.
- Fig.3A shows scRNA-seq datasets generated from two human TNBC primary tumors were integrated with eight normal mammary datasets.
- VCAM1-positive vascular endothelial cells from clusters 0 and 4 Top panel of Fig.
- EO771 tumors showed significantly upregulated CCL2, SDF-1a1ct and P- /E-selectin by qPCR relative to untreated contralateral tumor that peaked on day 4 post RT (Fig. 4B).
- CCP enucleated cells (1x10 6 labeled with DiD) dye
- the animals were sacrificed 24 hours later. Both tumors were then resected, and processed for FACS quantification of enucleated cells.
- Tables 3-5 illustrate: vector summary of the vector encoding IL-12; vector components of the vector encoding IL-12; and a nucleic acid sequence (SEQ ID NO: 1) of the vector encoding IL-12.
- Table 3. Vector summary of the vector encoding IL-12 Table 4.
- Vector components of the vector encoding IL-12 WSGR Docket No.53712-720.601
- WSGR Docket No.53712-720.601 Table 5.
- Fig.8D shows that CCP MSCs were infected with lentiviruses encoding scIL-12 and a stable resistant cell line generated by drug selection, then enriched by fluorescence- activated cell sorting (FACS) using anti-IL-12 monoclonal antibody (mAb) to select the top 1% cells expressing the highest amounts of scIL-12, designated CA-scIL-12 MSC parent.
- FACS fluorescence- activated cell sorting
- mAb anti-IL-12 monoclonal antibody
- CA-IL-12 readily homed to and integrated into micro- (93 ⁇ 11%) and macrometastasis (67% ⁇ 15%) in the lungs, which was similar to CCP enucleated cells (97 ⁇ 11% and 59 ⁇ 9%). Changes were not noted in integrated enucleated cells as in Fig.5. Strikingly, 93 ⁇ 11% and 97 ⁇ 11% of metastases observed showed infiltrated CA-IL-12 and CCP enucleated cells, respectively.
- CA-IL-12 product has significant potential to clear the lungs of micrometastatic disease, which has implications as an adjuvant therapy for TNBC as well as late-stage metastatic cancers.
- a single i.v. dose of CA-IL-12 did not impact the number of macrometastasis indicating that additional doses of CA-IL-12 are not necessary to impact large metastatic nodules.
- CA-scIL-12 with similar findings.
- Fig.10A illustrates an exemplary design of the enucleated cell expressing cell membrane tethered IL-15.
- the IL-15 is connected to the IL-15 receptor alpha by a linker.
- a signal peptide can also be connected to the IL-15.
- the fusion of IL-15 receptor alpha can increase IL-15 activity and response.
- Fig.10B illustrates a non-limiting example of a vector map for a vector encoding IL-15.
- Fig.11A illustrates a schematic for engineering the hTERT-MSC for expression both WSGR Docket No.53712-720.601 scIL-12 and IL-15R ⁇ and the subsequent enucleation of the hTERT-MSC.
- Fig.11B illustrates hTERT MSCs infected with two lentiviruses encoding constructs for either scIL-12 or IL-15R ⁇ . Following drug selection, cells were FACS sorted for single cell clones. Clone 4 was enucleated to generate enucleated cells expressing both scIL-12 and IL-15R ⁇ , and receptor expression was analyzed by FACS at the indicated time points.
- Fig.11C illustrates functionality of expressing membrane-bound IL-12, IL-15, or a combination of both IL-12 and IL-15.
- Pan-T cells were isolated from C57BL/6 mice.1.4x10 ⁇ 6 Pan-T cells/2 ml were co-cultured with hTERT MSCs expressing surface IL-12 a+b, hTERT MSCs expressing surface IL-15 R ⁇ , or hTERT MSCs expressing surface IL-12 a+b & IL-15 R ⁇ .
- 1.4x10 ⁇ 6 Pan-T cells/ml were co-cultured with hTERT MSCs without transfection or with IL-12 a+b transfection for 1 hour. The T cell only was taken as a negative control.
- CA-IL-12 and CA-scIL-12 Comparing the potential of CA-IL-12 and CA-scIL-12 to induce antitumor immunity against primary orthotopic TNBC tumors as well as secondary tumors in lungs and liver. Changes can be measured in a panel of key protein, gene, and immune cell biomarkers that report immune activation in the TME using established preclinical murine models of TNBC. The ability of CA-IL-12 medicines to transform the TME from relatively immunologically “cold” to “hot” tumors based on established biomarkers of antitumor immunity can be assessed. Changes in tumor regression and metastatic burden of CA-IL-12L medicine in combination with immune checkpoint blockade (ICB) therapy can be detailed.
- IRB immune checkpoint blockade
- the biodistribution of engineered MSCs and enucleated cells were monitored by bioluminescence.
- the mouse ear dermis was treated with WSGR Docket No.53712-720.601 LPS and i.v.-injected with 3D cultured CCP (CXCR4, CCR2, and PSGL-1) MSC or CCP enucleated cells each transfected with firefly luciferase mRNA.
- Mice were IP injected with D- luciferin at indicated time points after i.v. injection and mouse organs were subjected to bioluminescence imaging with IVIS Lumina Series III. Representative images were shown from two independent experiments in Fig.12A.
- significant numbers of 3D CCP enucleated cells rapidly home to SDF-1 ⁇ , CCL2, and P-selectin produced within inflamed tissues within 2 hours post injection (Fig.13A and Fig.13B).
- Fig.13A and Fig.13B show that CCP enucleated cells home better to the inflamed mouse ear than MSCs.
- Primary tumors can be formed by inoculating 4T1 or E0771.LMB TNBC cells (50,000 in 50 ⁇ L) orthotopically into the inguinal mammary fat pad (mfp), and tumor growth can be monitored using digital calipers and by whole body luminescence. Under these conditions, primary tumors measuring 100 mm 3 form reproducibly (100% of mice) between 14-18 days.
- Pulmonary metastases can be formed by seeding TNBC cells by tail vein injection (200 ⁇ L).
- liver specific metastases can be established by standard hemi spleen injection. These transplantation models generate secondary tumors in nearly 100% of mice within 14 days and secondary tumor growth can be monitored using whole body luminescence BLI.
- enucleated cells can be labelled with Vybrant DiO dye (3,3'- Dioctadecyloxacarbocyanine perchlorate ( ⁇ ex 484 nm/ ⁇ em 501 nm) for direct fluorescence imaging (Figs.5-7) or PCR using human mitochondrial DNA loci.
- Vybrant DiO dye (3,3'- Dioctadecyloxacarbocyanine perchlorate ( ⁇ ex 484 nm/ ⁇ em 501 nm) for direct fluorescence imaging (Figs.5-7) or PCR using human mitochondrial DNA loci.
- Animal weight and tumor size can be recorded by BLI and analyzed semi-quantitatively by luminoscore and compared across groups by two-way ANOVA. Growth of primary tumors can be terminated when tumors reach 2,000 mm 3 or animals show signs of physical distress.
- mice euthanized and mammary fat pad (mfp), lungs, liver, heart, kidney, spleen as well as inguinal and popliteal lymph nodes excised and profiled for changes in health and immune biomarkers.
- mfp mammary fat pad
- Portions of each tissue can be prepared for fluorescent microscopy, IHC, nanostring analyses, or disaggregated into single cell suspensions for flow cytometry (FACS).
- FACS flow cytometry
- Serum and tissue samples from tumor bearing mice can be used for measurements of IL-12 and its effector IFN- ⁇ .
- tissue and serum concentrations of IL-12 and IFN- ⁇ can be measured by ELISA and by measuring changes in IL-12-induced biomarkers IFN- ⁇ , PD- 1/PD-L1, CXCL9, and CXCL10 by RT-PCR.
- Host-derived vs enucleated cell-derived IL-12 mRNA expression in breast, spleen, and liver by RT-PCR using oligonucleotide primers that distinguish innate host and engineered forms of IL-12 mRNAs can be measured.
- Tissues can also be examined for changes in 200 nCounter® Inflammation Biomarkers using a standard NanoString nCounter Analysis.
- Tissues and tumors can be collected for FACS analysis of key infiltrating leukocyte populations, including: CD8+ T cells (CD45.2+CD8+CD3+CD4-), CD4+ T cells (CD45.2+CD8- CD3+CD4+); T regulatory cells (CD45.2+CD4+CD25+FoxP3+); M1 macrophages (CD45+Ly6c-F4/80+MHC II+); M2 macrophages (CD45+Ly6c-F4/80+MHC II-); dendritic cells (CD45+ and Btla+Flt3+ or Ly-6C+TLR7+TLR9+), activated NK cells (CD45+CD3-NK1.1+ and CD107A, Granzyme B+ IFN- IFN-y+), and mature memory effector T cells (CD45ROne
- the remaining tumors can be split in half for analysis by ELISA and IHC.
- One set of halves can be analyzed by ELISA for IL-12 and IFN- ⁇ levels.
- the other half can be used for IHC staining with anti-CD8, anti-CD4, anti-FoxP3, and PD-1 and PD-L1 antibodies.
- the intratumor location and number of infiltrating leukocytes of each type can be quantified by counting immunopositive cells in 10 high-powered (400X) within the tumor and tumor/stroma interface. For FACS and IHC, the relative number of each leukocyte type can be compared between groups using two-way ANOVA.
- CA-IL-12 or CA-scIL-12 treatment can also increase the number of activated cytotoxic effector cells locally in the tumor containing tissues, peripherally in inguinal, and popliteal lymph nodes as measured by IFN- ⁇ and Granzyme B-secreting (or expressing) cells.
- activated cytotoxic effectors cells cannot be present in peripheral non-tumor bearing tissues.
- no adverse health, weight loss, or organ pathology can be noted in IL-12 treated animals.
- CA-IL-12 and CA-scIL-12 can induce adaptive and innate immune responses that can reprogram the immunologically “cold” TME into a “hot” TME in primary tumors and secondary tumors in lungs and liver without overt animal toxicity.
- the proposed dosing regimen of CA-IL-12 and CA-scIL-12 can slow tumor growth and metastatic progression, and this response is likely be attenuated by IL-12/ IFN- ⁇ induced immune cell exhaustion due to upregulation of PD-1/PD-L1 signaling, leading to reduction in primary and secondary tumor burden. Therefore, local delivery of IL-12 medicines in combination with anti-PD-1 therapy can result in more robust and sustained antitumor and antimetastatic activity.
- Example 1 Data discussed in Example 1 and Example 6 indicates that IT administration of CA-IL- 12 ignites a favorable shift in the composition of infiltrating immune cells in the TME without adverse health events, including: a) five-fold increase in CD8+ cells, b) two-fold increase in the M1/M2 ratio and c) two-fold decrease in CD25+ T regulatory cells, d) no or minimal changes in animal health as indicated by body weight, serum IFN-IL-12/IFN-y levels, and pathology analyses of the liver and other vital organs. Similar changes in immune cell composition in the TME and health measures in mice receiving CA-IL-12L medicines injected i.v. can be considered as criterion for success of the experiments described in this example.
- CA-IL-12 activates innate and adaptive immunity in tumor tissue better than CA-scIL- 12.
- CA-IL-12 and CA-sc-IL-12 are equally competent with regards to their ability to home to and interdigitate within secondary TNBC tumors. It is expected that CA-scIL-12 can show the most favorable toxicity profile since membrane tethered IL-12 has limited access to the circulation relative to secreted forms of extracellular IL-12; however, its efficacy may be inferior compared to CA-IL-12. If this is the case, CA-IL-12 development can be continued, but only if it shows a favorable toxicity profile based on the following criteria.
- IFN- ⁇ is the prime mediator of both the beneficial and adverse effects of high dose rIL-12 immunotherapy. This relationship is further complicated by the observations that: 1) humans are significantly more sensitive to IL-12/ IFN- ⁇ toxicity than mice, 2) direct measurements of IFN- ⁇ in tissue in humans have not been determined although tissue IFN- ⁇ has been linked to toxicity. The concentrations of serum IFN- ⁇ can be determined and examined to see if they remain lower than concentrations known to be toxic in humans. For reasons stated above, tissue IFN- ⁇ can also be measured and its association with toxicity can be determined.
- a threshold for IFN- ⁇ toxicity can be set at 5 ng/mL, and if CA-IL-12 produces serum concentrations of IFN- ⁇ ⁇ 5 ng/mL than this modality of localized IL-12 delivery can be dismissed. Leveraging the genetic versatility of the enucleated cell platform, two next generation enucleated cell products can be developed with improved benefit/risk ratios.
- CA-scIL-12 can be engineered to co-express known immune cell surface anchored co-stimulatory proteins 4- 1BBL and/or CD40L, which is expected to synergistically drive potent immune activation in combination with scIL-12 within the TME and maintain a safe profile.
- CA-IL-12 can be engineered to secrete IL-12 that is conditionally activated by the high proteolytic activity in the TME.
- IL-12 can be engineered with a peptide mask with a protease linker that prevents binding to the IL-12 receptor using a similar approach for masking cytokines and antibodies.
- the linker sequence was selected using cellular libraries of peptide substrates (CLiPS) for its responsiveness to multiple tumor-associated proteases, including urokinase-type plasminogen activator (uPA), membrane-type serine protease 1 (MT-SP1/matriptase), and legumain, all of which are strongly upregulated in the tumor microenvironment of most human tumors.
- uPA urokinase-type plasminogen activator
- MT-SP1/matriptase membrane-type serine protease 1
- legumain all of which are strongly upregulated in the tumor microenvironment of most human tumors.
- the mask contains specific protease consensus cleavage sites that upon exposure to high protease activity in the TME removes the mask and restores IL-12 function. Because proteolytic activity is largely absent in blood and normal tissues IL-12 bioactivity is retained within the TME.
- Criteria for selecting CA-IL-12 medicine can be based on detecting a favorable shift in the composition of infiltrating immune cells in the TME without adverse health events while the experiments detailed for reducing metastatic burden, improving overall animal survival, and inducing durable antitumor immunity can be conducted using; a) CA-IL-12, b) CA-scIL-12, c) WSGR Docket No.53712-720.601 CA-scIL-12 engineered to contain additional cell surface immune activators 4-1BBL/CD40L or d) CA-IL-12 secreting protease activated IL-12. The medicine developed can then be referred to as CA-IL-12L.
- CA-IL-12L can then be further evaluated for efficacy.
- Example 9 Determination of the ability of IL-12 medicine (CA-IL-12L) in combination with ICB therapy to reduce metastatic burden, improve overall animal survival, and induce durable antitumor immunity [0227] Coupling the potent adaptive and innate immune activity of IL-12 with ICB is a powerful combinatorial therapy to overcome ICB resistance and drive antitumor immunity. While IL-12 monotherapy can reduce tumor progression, it is not sufficient to drive durable antitumor responses.
- ICB therapy (Atezolizumab) have been achieved in the adjuvant setting and tumor-free and overall survival in mice whose primary tumors are resected prior to CA-IL-12L can be evaluated, and anti-PD-1 therapy as a clinical trial correlate.
- 4T1 and EO771 tumors can be used, which are refractory to ICB therapy as is the case with most human TNBCs.
- Primary tumors can be formed following orthotopic transplantation of 4T1 or E0771.LMB TNBC cells as described previously. At day 14, primary tumors can be excised, and spontaneous metastases can be monitored by bioluminescence imaging (BLI). Under these conditions, tumor weights at resection show a low coefficient of variation ( ⁇ 15% CV).
- Animal weight and tumor size can be recorded by BLI and analyzed semi-quantitatively by luminoscore once a week and compared across groups by two-way ANOVA. Metastases can be measured by marking the whole body minus the 4th inguinal mfp as a ROI. Survival rates can be determined from Kaplan-Meier plots and the log-rank test. The durability of the antitumor response can be evaluated by rechallenging surviving mice (from group 10) with tumor cells. In these experiments, in mice with no measurable primary tumors 60 days after treatment, tumor cells can be reintroduced into the 4th mfp and tumor growth can again be monitored by BLI. These experiments can be terminated when tumors reach 2,000 mm 3 or show signs of labored respiration.
- CA-IL- 12L medicine in combination with ICB therapy can yield an 80% overall response rate with ⁇ 50% reduction in metastatic burden, and an improved overall animal survival of at least 20 days with a ⁇ 40% complete response rate based on Kaplan–Meier plots, the log rank test, and the Cox proportional hazards test.
- CA-IL-12L in combination with ICB therapy can generate durable antitumor immunity ( ⁇ 120 days disease free) and prevent tumor regrowth following tumor rechallenge in 100% of the surviving animals.
- CA-IL-12L can be present in tumor tissue but fail to induce immune cell infiltration robust enough to drive anticancer immunity. If this is the case, CA-IL-12L may be engineered to secrete potent NK and cytotoxic T cell chemoattractants (CXCL9 or CXCL10). On the other hand, if CA-IL-12L does promote immune cell infiltration, activate IL-12 biomarkers, and prevent immune exhaustion markers as expected, but fails to impact overall survival an in-depth analyses of the infiltrated immune cell phenotypes and immune cytokines can be performed to identify potential new targets and immunomodulators that could be targeted by bioengineered enucleated cells alone or in combination with ICB therapy.
- CXCL9 or CXCL10 cytotoxic T cell chemoattractants
- the PyMT mouse is ideally suited as a model for testing ICB in combination with CA-IL-12L because the primary tumors are ICB refractory and substantial work supports a role for innate and adaptive immune systems in metastasis regulation.
- MMTV-PyMT tumor vasculature overexpresses CCP enucleated cell ligands.
- CD31-positive endothelial cells within MMTV-PyMT tumors were FACS sorted and utilized for 10x Genomics scRNA-seq (Fig.14A and Fig.14B).
- mice can be euthanized on the day following the last treatment (day 90 when >90% of mice have metastatic disease).
- Animal health and biomarker analyses of blood and tissues can be performed as described previously with minor modifications.
- the presence of primary and secondary tumors in mfp, lungs, liver, and brain can be evaluated by gross inspection at the time of necropsy and by H&E and IHC using specific PyMT (Novus, NB100-2749), CK18 (Abcam, EPR17347) and EpCam (Abcam, EPR20533-63) antibodies.
Abstract
Sont décrites des compositions et des méthodes pour traiter le cancer par administration d'une cellule énucléée, la cellule énucléée comprenant un ARN messager exogène (ARNm) codant pour un polypeptide de cytokine et des organelles pour exprimer le polypeptide de cytokine à partir de l'ARNm exogène, le polypeptide de cytokine étant exprimé par la cellule énucléée sur une surface de cellule. La cellule énucléée peut également comprendre un ARNm exogène codant pour une autre cytokine ou un autre inhibiteur de point de contrôle immunitaire.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63/477,464 | 2022-12-28 | ||
US63/591,857 | 2023-10-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024145168A1 true WO2024145168A1 (fr) | 2024-07-04 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111542595B (zh) | 经修饰的免疫细胞及其用途 | |
US11028177B2 (en) | Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells | |
KR101913293B1 (ko) | 탈모 질환의 치료 방법 | |
US20180118838A1 (en) | Flt3 directed car cells for immunotherapy | |
JP2021523110A (ja) | 遺伝子発現のためのナノ粒子及びその使用 | |
CN112673093A (zh) | 靶向flt3、pd-1和/或pd-l1的免疫疗法的组合物和方法 | |
CN111420032A (zh) | 用于治疗肿瘤的方法 | |
KR20070009637A (ko) | 암 세포 증식을 억제하는 항α5β1 항체의 용도 | |
WO2021207290A1 (fr) | Cellules immunitaires modifiées | |
CN114786686A (zh) | Gold控制的转基因的联合疗法 | |
KR20220100913A (ko) | Cd70을 표적화하는 유전자 조작된 t 세포를 사용하는 신세포 암종(rcc) 치료법 | |
Jafarzadeh et al. | Targeted knockdown of Tim3 by short hairpin RNAs improves the function of anti-mesothelin CAR T cells | |
KR20220116239A (ko) | 변형된 면역 세포의 제조에서 플라스미드 조합 및 이의 적용 | |
KR20220101128A (ko) | Cd70을 표적화하는 유전자 조작된 t 세포를 사용하는 cd70+ 고형 종양 치료법 | |
US10973843B2 (en) | Method for monitoring cancer and for regulation of semaphorin 4D to improve cancer immunotherapy regimens | |
KR20240007911A (ko) | Cd5-양성 암을 표적화하기 위한 키메라 항원 수용체 | |
US20220280566A1 (en) | Ubiquitination-lacking chimeric antigen receptor and use thereof | |
WO2024145168A1 (fr) | Compositions et méthodes pour traiter le cancer | |
KR20230160823A (ko) | 치료 전달을 위한 조성물 및 방법 | |
KR20240099228A (ko) | 조작된 nk 세포 및 이의 용도 | |
JP2021518149A (ja) | 免疫細胞増殖を促進する方法 | |
US20220119523A1 (en) | Treatment of cutaneous t cell lymphoma with targeting of cd47 pathway | |
US20200405763A1 (en) | Irf-4 engineered t cells and uses thereof in treating cancer | |
US20230338423A1 (en) | Targetable immune checkpoint for immunotherapy | |
US8309072B2 (en) | Irreversibly-inactivated pepsinogen fragments for modulating immune function |